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High-throughput genotyping and sequencing technologies have stimulated an accelerated 
pace of Mendelian gene discovery.  Forty-one novel genetic causes of skeletal dysplasia have 
been uncovered in the last two years.  The genetic heterogeneity of the skeletal dysplasias is 
extremely high, with 450 forms described.  Multiple organ systems can be affected, including the 
reproductive system.  I present the discovery of two different genes that are mutated in 
spontaneously occurring mouse mutants that cause skeletal dysplasia and infertility.  These 
discoveries demonstrate the value of mouse mutations for understanding the pathophysiology of 
disease and testing treatments. 
The peewee mouse exhibits female infertility and skeletal dysplasia associated with 
reduced progression of cells through the zones of the growth plate.  The phenotype is caused by a 
loss-of-function mutation in the gene that encodes natriuretic peptide receptor 2, Npr2.  Human 
NPR2 mutations cause a form of extreme short stature known as acromesomelic dysplasia, 
Maroteaux type (AMDM).  Nothing is known about the fertility of these patients.  We 
demonstrate that Npr2 loss-of-function affects growth by increased activation of the ERK MAPK 
pathway.  We can correct the Npr2pwe/pwe growth defect in explant cultures of embryonic bones 
with drugs that inhibit MEK1/2 action.  We also show that female infertility is rooted in the 
requirement for Npr2 activation to generate the cGMP necessary to maintain meiotic arrest of 
oocytes.  
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The chagun mouse exhibits severe short stature and male infertility.  The phenotype is 
caused by a hypomorphic mutation in a gene also mutated in human patients with a form of 
primordial dwarfism.  The fertility of these patients is unknown.  I demonstrate that chagun 
serves as a model for this human disorder.  I show that the growth insufficiency is caused by 
disorganization of the cells at the growth plate, and that male infertility is due to progressive 
germ cell loss.   
Both of these mouse mutations model human skeletal dysplasia disorders, predict 
infertility, illuminate the pathophysiology of the disorders and pave the way for the development 
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CHAPTER 1 
Skeletal Dysplasias in the Genome Era: Molecular Diagnostics, Outcomes Prediction and 
Improved Therapeutic Potential 
 
Outline: 
Overview of Early Skeletal Development and Endochondral Ossification 
The Skeletal Dysplasias 
Genetic Heterogeneity of Skeletal Dysplasia  
Skeletal Dysplasia Genetics: A Historical Perspective 
A Geneticist’s Best Friends: High-Throughput Technologies and Mutation Discovery 
How Mouse Models Impact Skeletal Dysplasia Research 
Signaling Pathways Implicated In Skeletal Dysplasias 
IMAGe Syndrome: The Importance of Imprinting 
Proteus Syndrome: A Disorder of Mosaicism 
INPPL1 Mutations in Opsismodysplasia 
cAMP signaling and Acrodysostosis  
FGFR2 and Bent Bone Dysplasia 
SMAD4 and Myhre Syndrome 
Epigenetics: Histone Acetyltransferase KAT6B/MYST4 Mutations Cause a Variety of Disorders 
Could Mutations in miRNAs Cause Severe Short Stature? 
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The Primordial Dwarfisms 
The Skeletal Ciliopathies 
A Missing Link: Mutations in POC1A Cause a Novel Form of Primordial Dwarfism That 
Exhibits Defects in the Primary Cilium 
Novel Skeletal Disorders of Unknown Etiology 
Future directions: How Mutation Discovery Advances Skeletal Dysplasia Research 




 Skeletal dysplasias result from disruptions in normal skeletal growth and development, 
and are a major contributor to severe short stature in humans.  They occur in approximately 
1/5000 births, and some of them result in lethality.  The Nosology and Classification of Genetic 
Skeletal Disorders is published once every five years.  In the two years since the most recent 
publication, 39 new genetic causes of skeletal disorders have been uncovered, and 11 novel 
skeletal syndromes have been described.  This remarkable rate of discovery is largely due to the 
expanded use of high-throughput genomic technologies.  This review is intended to supplement 
the most recent edition of the Nosology and Classification, and provide the reader with a 
historical appreciation of the field of skeletal dysplasia genetics.  We discuss the major 
contributions of mouse models to understanding the molecular mechanisms behind skeletal 
dysplasia phenotypes, and their utility in the development of therapies.  The rate of discoveries in 
genetics and molecular mechanisms is truly spectacular.  These advances hold great promise for 
diagnostics, risk prediction and therapeutic design.  
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Overview of Early Skeletal Development and Endochondral Ossification 
The bones of the skeleton are formed through two processes: intramembranous 
ossification and endochondral ossification.  Both of these developmental programs begin with 
the condensation of mesenchymal cells in areas of the body where a skeletal element will 
eventually form (1-3).  The condensations that will form the cranium, and parts of the clavicle 
and pubic bone, undergo intramembranous ossification, where the mesenchymal cells 
differentiate directly into osteoblasts that will transform the condensation into true bone tissue.  
This review will concentrate on genetic disorders of endochondral ossification. 
The bones of the body that form through endochondral ossification are mainly 
responsible for determining an individual’s final stature (2).  Early in endochondral ossification, 
the mesenchymal cells of the condensation differentiate into chondrocytes instead of osteoblasts.  
These intermediary chondrocytes will proliferate and undergo terminal hypertrophic 
differentiation, which directs the invasion of the vasculature into the nascent element, leading to 
the recruitment of osteoblasts (1-3). The infiltrating osteoblasts replace the dead or dying 
hypertrophic chondrocytes with mature bone matrix.  The progressive mineralization and 
maturation of the cartilage template occurs along its length (out from the primary ossification 
center), as well as at either end (secondary ossification centers).  As this new element begins to 
take on more characteristics of a true bone, a population of undifferentiated chondrocytes 
becomes sealed within either end of the forming element.  These pools of reserved chondrocytes 
are known as the epiphyseal growth plates, and they regulate the growth of the skeletal elements 
and the individual over time.  
The growth plate is a highly organized tissue.  It is composed of three distinct zones: the 
resting zone, the proliferative zone, and the hypertrophic zone, which culminates in chondrocyte 
	   4	  
cell death (1-4) (Figure 1.1).  Lesser-differentiated cells in the resting zone are recruited to the 
enter the proliferative zone where they divide perpendicular to the plane of the growth plate, 
intercalate over each other, and adopt a flattened shape to form pillars of discoid chondrocytes 
(3-6).  Eventually, the cells in the proliferative zone receive signals that promote their further 
differentiation into hypertrophic chondrocytes.  Once in the hypertrophic zone, the cells express 
a new combination of transcription factors, signaling molecules, and matrix proteins.  
Chondrocyte hypertrophy also leads to a tremendous increase in cell volume and apoptosis.  
Osteoblasts will then replace the chondrocytic remnants with bone matrix at the ossification 
front, where the newest bone tissue is formed in the growing element.  
The Skeletal Dysplasias 
Numerous genetic mutations have the ability to disrupt the organization and function of 
the growth plate (1, 2, 7-9).  Studies in humans and mice have discovered many genes that 
regulate growth plate architecture and the rates of chondrocyte proliferation and/or 
differentiation (Figure 1.2).  In humans, mutations in these genes profoundly impact the growth 
of the individual such that he or she is unable achieve a normal adult height for his or her age, 
ethnicity, and sex.  These disorders of skeletal growth are known as the skeletal dysplasias.  
There are over 400 skeletal dysplasias documented in the medical literature (8).  They are 
predicted to occur in approximately 1/5000 children (2), and they can have a wide range of 
effects on the individual from relatively mild effects to lethality.  Most lethal forms of skeletal 
dysplasia result from thoracic hypoplasia, where the thoracic cage is not large enough to allow 
for proper lung development (10).  In such cases, the infant dies of respiratory distress soon after 
birth.  
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Figure 1.1. Formation of the growth plate and growth plate architecture.  On the left is a 
diagram of a typical long bone, which forms early in embryonic development through the 
condensation of mesenchymal cells that then differentiate into chondrocytes.  The hypertrophy of 
these chondrocytes promotes the vascularization of the element, which brings osteoblasts to the 
element to facilitate the addition of true bone matrix.  The diaphysis, or shaft of the bone, bridges 
the ends, or epiphyses of the bone.  The epiphyseal growth plates lie between these two 
structures, retain their chondrocytic identity, and serve as a pool of reserved chondrocytes to 
regulate growth of the long bone throughout one’s growth period.  On the right is a section 
through a 3-week old mouse tibial growth plate stained with hematoxylin and eosin.  The zones 
of the growth plate are clearly recognizable.  As the lesser-differentiated cells in the resting zone 
begin to divide, they enter the proliferative zone.  This zone is characterized by chondrocytes 
that form columns of flattened chondrocytes that resemble stacks of coins.  These dividing cells 
terminally differentiate in the hypertrophic zone, where they greatly increase their cell volume 
and alter their gene expression profile to express different transcription factors, enzymes, and 
extracellular matrix proteins.  At the edge of the hypertrophic zone, known as the ossification 
front, osteoblasts will begin to lay down mature bone tissue in the place of the dying 
hypertrophic chondrocytes.  This process is spatially and temporally regulated to allow for 
coordination of the growth of the long bones throughout an individual’s growth period, ensuring 
that they grow to a normal adult height. 
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Many forms of skeletal dysplasia result in severe short stature, but are compatible with 
life.  In some cases, other organ systems are affected.  Disorders that affect the skeleton and the 
reproductive organs have been documented (11-18) (Table 1.1).  Also, a significant number of 
skeletal dysplasia patients have been reported to have hearing loss (2, 16, 19, 20).  In patients 
with achondroplasia, the most common non-lethal form of skeletal dysplasia (2), hearing loss 
could be due to chronic otitis media (19), but the involvement of otitis media in hearing 
impairment in other forms is not well documented.  Individuals may also have neurological 
involvement and vision problems (2).  It is recommended that patients are carefully monitored 
for all of these potential complications, as they may require immediate intervention (2, 21). 
Studies focused on individuals affected with achondroplasia, the most common form of 
skeletal dysplasia, reveal the impact on quality of life that are likely to apply to other skeletal 
dysplasias (22).  Achondroplasia patients report effects on overall health, employment 
opportunities, income, and intimate relationships.  Adolescence can be a difficult time, with the 
effects of normal adolescence being exacerbated and extended into adulthood.  Support groups 
for individuals with severe short stature can be helpful.  Perhaps the most well known 
organization is Little People of America, which holds annual meetings and gatherings and 
provides skeletal dysplasia patients a venue through which they can share their experiences and 
network (2). 
Currently, there are no pharmacological therapies available for individuals affected with 
any of the various forms of skeletal dysplasia, although there are some promising candidates.  
Growth hormone therapy can accelerate the growth rate, but in cases of idiopathic short stature, 
GH therapy does not substantially improve target height (23).  Controversial surgical procedures 
have been performed that successfully lengthened the limbs of a child, but the  
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surgeries are numerous, expensive, fraught with potential complications, and require dedication 
of much of one’s childhood years to medical care (2, 21). Molecular diagnosis of skeletal 
dysplasias is highly desired, and treatment options are sought after by many patients and their 
families. 
The Genetics of Skeletal Dysplasia 
Skeletal dysplasias have historically been characterized by the inheritance pattern, 
associated symptoms, and radiological features.   These classifications are confounded by the 
Table 1.1 Skeletal Disorders that Affect Reproductive Organs 
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fact that mutations in the same gene can cause many different forms of skeletal dysplasia (8).  
The best examples of this phenomenon are the forms that result from mutations in FGFR3, the 
gene that encodes fibroblast growth factor receptor 3.  Remutation of the same codon in FGFR3 
creates an activating mutation that causes semi-dominant achondroplasia, but patients with 
alternative mutations have thanatophoric dysplasia (type I or II) and die in utero or very shortly 
after birth of respiratory failure.   Another obstacle in classifications is that mutations in different 
genes can cause the same form of skeletal dysplasia.   Osteogenesis Imperfecta (OI) is a premier 
example of this phenomenon.  Genes that encode collagens are a major cause of the various 
forms of OI (COL1A1 and COL1A2), but so are genes that encode molecular chaperones 
(SERPINH1, FKBP10).  There are also cases in which the affected individual has many 
hallmarks of a particular form, but additional clinical features that have not been previously 
associated with that form of skeletal dysplasia (27).  These cases may involve modifying loci of 
the various forms of skeletal dysplasia. 
Genes implicated in skeletal dysplasias encode products that are involved in a diverse 
array of cellular processes.  The major processes include signal transduction, extracellular matrix 
components, control of protein trafficking and glycosylation, and control of gene expression at 
the levels of transcription, RNA processing and translation (Table 1.2).  Among the newest 
discoveries are genes that influence ciliogenesis and cilia maintenance. 
Skeletal Dysplasia Genetics: A Historical Perspective 
 Throughout the 1980s, defects in collagen genes reigned as the major genetic cause for 
such conditions as Osteogenesis Imperfecta (COL1A1) (28, 29), Stickler syndrome (COL2A1) 
(30), and spondyloepiphyseal dysplasia (COL2A1) (31).  These studies made use of genetic 
material collected from nuclear families with multiple affected individuals, and utilized such 
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techniques as linkage analysis, positional cloning (30-32) and traditional Sanger sequencing to 
uncover the causative mutations.  The discovery of collagen mutations in skeletal disorders 
heralded a shift in the field from cataloguing the clinical manifestations of the disorder to 
understanding genetic causes that could be used for molecular diagnostics and risk prediction.   
 These successes were quickly followed by discovering the common genetic etiologies of 
achondroplasia and thanatophoric dysplasia.  Achondroplasia does not co-segregate with 
COL2A1, meaning that the disorder was not due to mutations in this gene (33).  In 1994 three 
groups mapped achondroplasia to the distal region on the small arm of human chromosome 4 
(34-36).  All three studies had several (6-18) unrelated, nuclear families with multiple affected 
individuals to analyze for linkage analysis.  A locus on chromosome 4p16.3 co-segregated with 
achondroplasia in all of the families, indicating no evidence for genetic heterogeneity.  The 
analysis was performed in roughly the same way in all studies.  First, sets of polymorphic 
microsatellite markers were tested across the genome to narrow the locus to a large region of a 
chromosome.  This was followed by finer mapping with additional polymorphic markers 
flanking the original marker.  Munnich and colleagues included patients with hypochondroplasia, 
which was thought to be allelic to achondroplasia at that time.  Their results supported this 
hypothesis, as both conditions mapped to the same region on chromosome 4 (34).  This region 
included several candidate genes, one of which was FGFR3. 
 Only a few months after achondroplasia and hypochondroplasia were mapped, the 
achondroplasia mutation in FGFR3 was discovered (37, 38).  Astonishingly, all of the patients 
screened had the same nucleotide disrupted—the guanosine at position 1138 of the FGFR3 
transcript was substituted with an adenosine or a cytosine resulting in a missense mutation that 
substituted an arginine for a glycine at codon 380 (G380R).  The glycine residue lies within the 
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transmembrane domain of the receptor.  At the time, the detrimental effects of the mutation were 
speculated to cause a dominant-negative effect, but it was not clear how this would occur.  Soon 
after the publication of these findings, a large-scale screen of an additional 154 achondroplasia 
patient samples was published and confirmed the importance of residue 380—all of these 
patients had the same missense mutation, G380R.  The guanosine’s location in a CpG island is 
speculated to make this region a hot spot for mutagenesis (37), but there is no clear molecular 
explanation as to what makes this nucleotide so vulnerable.  Subsequently, normal FGF signaling 
was shown to have an inhibitory affect on the regulation of skeletal growth (39), and the 
molecular mechanism underlying achondroplasia was realized to be constitutive activation of 
FGFR3 by the G380R substitution (40, 41).  
 Both types of thanatophoric dysplasia and hypochondroplasia are caused by mutations in 
FGFR3.  Missense mutations in the extracellular portion (R248C) and the second kinase domain 
(K650Q) of FGFR3, cause thanatophoric dysplasia types I and II, respectively (42).  
Thanatophoric dysplasia is also caused by point mutations that disrupt the normal termination 
codon, resulting in read-through translation into the 3’ untranslated region of the FGFR3 
transcript (43).  Patients with hypochondroplasia are negative for the FGFR3 G380R mutation 
(44), but have a missense mutation (N540K) in the first kinase domain of the receptor (45).    
 The time elapsed from the initial mapping of the achondroplasia mutant locus to the 
discovery of all of these FGFR3 mutations was only about 1 year.   This timeline is impressive 
given the technology of the time.   Importantly, all of these studies took place before the release 
of the sequence of the human genome.   FGFR3 mutations cause additional types of skeletal 
dysplasias and the related family members FGFR2 and FGFR1 are also involved (7, 8).  The rate 
of mutation discovery has accelearated, given the availability of the reference genome sequence 
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and high-throughput genomic mapping and sequencing technologies, which have revolutionized 
how these types of studies are conducted today. 
A Geneticist’s Best Friends: High-Throughput Technologies and Mutation Discovery 
Table 1.2 outlines the genetic causes of disorders that affect skeletal growth and/or 
development that have been discovered since the last edition of the Nosology of Skeletal 
Disorders.  Of the 43 studies included, 36 of them  (84%) make use of some type of high-
throughput technology, including whole genome SNP mapping, comparative genomic 
hybridization arrays, whole exome or genome sequencing, and targeted enrichment of a locus 
followed by next-generation sequencing (Table 1.2).  More than half of the mutations listed 
(65%) were discovered through the use of some form of next-generation sequencing of patient 
genomic DNA samples.  Clearly, the strategy has changed.  
Approximately half the mutations in Table 1.2 were discovered by exome sequencing.  
As more efficient and cost-effective sequencing technologies are developed (46, 47), whole 
genome sequencing will ultimately become the preferred strategy, likely eliminating genetic 
mapping and exome sequencing.  Most patients will have their genomes sequenced, and the 
unique variants that are predicted to affect function will be confirmed by Sanger sequencing 
technology (47).  We are truly in an age of revolutionary genomic analysis, which will 
substantially aid in the diagnosis, understanding, and treatment of many genetic disorders (46), 
including those that affect the skeleton. 
How Mouse Models Impact Skeletal Dysplasia Research 
 Studies conducted in mice have contributed to understanding the genetic basis of skeletal 
dysplasias, the pathophysiology of disease and therapeutic testing (48-57).  In many of these 
studies, the description of the mouse model was soon followed by publications of mutations in 
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Table 1.2 Causative Mutations of Skeletal Disorders Discovered After the Publication of the 2011 Nosology 
Primary Cilium 
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Mosaicism proliferation, and 
cell growth  
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human patients that cause a similar skeletal phenotype.  Recently, an ENU-induced mutation in 
mice was found to be a model of achondrogenesis type 1A in humans (57).  This autosomal 
recessive mutation caused perinatal lethality, severely disrupted endochondral ossification, 
greatly reduced the mineralization of skeletal elements, and disturbed the trafficking of 
extracellular matrix proteins, resulting in acute intracellular stress in affected chondrocytes.  
Mapping of the mutant locus to mouse chromosome 12 was conducted using a SNP array, and 
was subsequently winnowed down to a 3.7 Mb interval.  Screening of candidate genes in the 
interval led to the discovery of a nonsense mutation (c.5003TàA, p.L1668X) in Trip11, which 
encodes GMAP-210, or Golgi microtubule-associated protein 210.  Due to the overlapping 
phenotypic characteristics between the Trip11-/- mice and achondrogenesis type 1A in humans, 
the authors considered Trip11 as a candidate gene for this form of skeletal dysplasia.  They 
screened 10 patients diagnosed with achondrogenesis type 1A for mutations in Trip11, and all 10 
of them harbored mutations in this gene.  Clearly, the mouse can contribute to the genetic 
diagnosis of patients with skeletal dysplasias because of the phenotypic similarities. 
	   17	  
The true power of mouse models of the skeletal dysplasias is in unraveling the molecular 
mechanisms that lead to the pathology and for testing potential therapies.  The data collected 
from skeletal dysplasia patients are usually limited to measurements or samples that can be 
gathered with minimal invasiveness: radiographs, photographs, height, weight, hormone 
measurements, and isolation of skin fibroblasts, blood leukocytes and genomic DNA.  If the 
patient is affected with a lethal form of skeletal dysplasia, and the investigators have consent to 
collect tissue, there may be additional analyses performed on the tissues collected, including 
histological analysis of the growth plate.  The mouse models provide researchers with accessible 
tissue throughout development and the potential for assessing genetic interactions with genetic 
complementation studies (94, 95).  Thus, mouse studies have contributed greatly to our 
understanding of how gene mutations result in the growth defects and skeletal anomalies.  
Recent development of pharmacologic therapies to treat skeletal dysplasias has relied 
heavily on mouse models for testing efficacy and efficiency (96-102).  Developing a therapy for 
achondroplasia is a top priority, given that it is the most common form (2).  Two main 
approaches are being taken: thwarting the over-activity of the mutant receptor directly by 
inhibiting FGFR3 (96, 100), or treating with C-type natriuretic peptide (CNP), the ligand for an 
opposing pathway.  Supplementation with C-type natriuretic peptide (CNP), the ligand for 
natriuretic peptide receptor 2 (NPR2), inhibits the activation of the MEK/ERK MAPK pathway, 
which lies downstream of FGFR3 activation (103).  The inhibition of MEK/ERK occurs through 
the generation of cyclic GMP, which inhibits RAF-1 and leads to inhibition of the downstream 
components of the pathway.  These mechanistic insights are supported by experiments conducted 
on chondrocyte cell lines (103), and our recent demonstration of ERK pathway overactivation in 
mice with a loss-of-function mutation in Npr2 (102).   
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CNP treatment improves growth in a mouse model of achondroplasia (96, 104-106).  
Patients with loss-of-function mutations in the CNP receptor, NPR2, have acromesomelic 
dysplasia, Maroteaux type (AMDM) (107), and would obviously not benefit from this mode of 
therapy.  We took advantage of a mouse model of AMDM, known as the peewee mouse 
(Npr2pwe/pwe) to test the efficacy of drugs that act downstream of Npr2.   Inhibition of the 
MEK/ERK MAPK pathway improved fetal tibia growth in cultures (102).  This type of 
intervention may be adapted as a therapy for AMDM patients.  This illustrates the power of 
mouse models to understand of the pathophysiology of skeletal dysplasias and to assess 
treatments.  
Signaling Pathways Implicated In Skeletal Dysplasias 
Several signaling pathways are known to regulate a chondrocyte’s transition through all 
three zones of the growth plate (Figure 1.2).  Indian hedgehog (IHH), Parathyroid hormone- 
related peptide (PTHrP), Fibroblast growth factor (FGF), C-type natriuretic peptide (CNP), TGF-
beta, Bone Morphogenetic Protein (BMP), Notch, and Wnt (canonical and non-canonical)  
signaling pathways all aide and guide chondrocytes properly through the growth plate (1, 3, 7) 
(Figure 1.2).  The function of these signaling pathways in growth, patterning, and mineralization 
are illustrated in Figure 1.2 and have been reviewed extensively (1, 3, 7).   We will discuss 
selected recent genetic discoveries in the arena of signal tranduction and skeletal dysplasia.   
Mutations in signaling-associated genes continue to be discovered in many forms of 
skeletal dysplasia.  Opsismodysplasia patients have been found to have loss-of-function 
mutations in INPPL1, which encodes SHIP2 and is a mediator of signaling through the 
phosphotide-inositol phosphate pathway (69, 70, 108).  Mutations have been uncovered in the  
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Figure 1.2.  Interaction of signaling pathways in the growth plate.  A number of signaling 
pathways are active in the various zones of the growth plate, and many of them exhibit cross-talk 
with one another.  The combination of these signals allows the cells within the growth plate to 
respond accordingly depending on where and when they encounter activation of the pathway.  
Arrows indicate an activation of one pathway by another.  A line with a bar-shaped arrowhead 
indicates inhibition of that pathway.  Finally, dashed lines indicate that there is evidence that 
there is cross talk between the pathways, but the nature is not clear.  For example, PI3K is 
thought to affect CNP, IHH, and PTHrP signaling pathways.  Many of these pathways also have 
been implicated in many different forms of skeletal dysplasia. (CNP: C-type natriuretic peptide, 
FGF: Fibroblast growth factor, BMP: Bone morphogenetic protein, PI3K: Phosphoinositide-3 
Kinase, IHH: Indian hedgehog, PTHrP: Parathyroid hormone related peptide)   
 
PTHRP-mediated cyclic AMP (CAMP) signaling pathway that cause acrodysostosis (14, 17, 25, 









































	   20	  
TGFβ-BMP signaling effector SMAD4 that have been shown to cause Myhre syndrome (16, 
109).  
Two skeletal disorders, IMAGe and Proteus syndrome, are caused by mutations in genes 
involved in critical signaling pathways (13, 73). These examples underscore the importance of 
the mode of inheritance of the causative mutation in the development of a patient phenotype.    
IMAGe Syndrome: The Importance of Imprinting 
IMAGe Syndrome is characterized by Intraunterine growth restriction, Metaphyseal 
dysplasia, Adrenal hypoplasia congenita, and Genital abnormalities (IMAGe) (24).  The IMAGe 
phenotype encompasses many different organ systems and leads to hypoplasia in the affected 
tissues.  The skeletal abnormalities present in these patients are variable, and include defects at 
the level of the growth plate (metaphyseal dysplasia, epiphyseal dysplasia, short arms and legs) 
and the bone tissue itself (osteopenia, delayed bone age) (13, 24).  This disorder is caused by 
mutations in CDKN1C, which encodes cyclin dependent kinase inhibitor 1 C, also known as 
p57Kip2.  CDKN1C is imprinted, and the maternal copy is expressed.  Thus, the lack of expression 
of the paternal allele contributes to the apparent autosomal dominant inheritance from the 
mother.  This phenomenon was observed in all the patients screened in a large five-generation 
Argentinian family.   
The IMAGe mutations (Table 1.2) occur specifically in the proliferating cell nuclear 
antigen (PCNA)-binding domain of CDKN1C.  This domain confers ubiquitin-targeted protein 
degradation of CDKN1C after PCNA-binding (13).  The mutant form of CDKN1C does not bind 
PCNA, resulting in abnormal stabilization of the cell-cycle inhibitor and the hypoplasia 
phenotypes.  CDKN1C blocks entry into S-phase, and expression of the mutant form in the 
proliferative zone could profoundly inhibit the rate of chondrocyte proliferation.  Transcriptional 
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activation of CDKN1C by C/EPBβ is thought to regulate the transition from proliferation to 
hypertrophic differentiation in the growth plate (110).  Inhibition of IMAGe growth plate 
chondrocyte division could cause cell cycle exit and premature differentiation into hypertrophic 
chondrocytes, resulting in dwarfism.  Targeted inhibition of CDKN1C in IMAGe patients could 
be therapeutic, if the problems of specificity and delivery could be overcome.   Parathyroid 
hormone-related hormone (PTHRP), is another therapeutic candidate because it promotes 
chondrocyte proliferation, and is thought to downregulate p57 (111).   
Proteus Syndrome: A Disorder of Mosaicism 
 The genetic etiology of Proteus Syndrome is a recent, highly celebrated discovery 
because of the role of somatic mosaicism.  Proteus Syndrome is a debilitating disorder 
characterized by patchy, asymmetrical hyperplasia that affects a variety of tissues, including 
bone and connective tissue (73, 112).  The disorder is incredibly rare, occurring in <1:1 million 
individuals.  The asymmetric nature of the disorder led to the hypothesis that it results from a de 
novo mutation occurring early in development, and only affecting a portion of cells in the 
embryo.  The mutation would cause abnormal cell division and growth.  This phenomenon is 
known as somatic mosaicism, where patients are composed of two populations of cells: normal 
cells, and cells that harbor the causative mutation.  Furthermore, cases are typically sporadic, 
lending more support to the somatic mosaicism hypothesis.   
The highly progressive rate of asymmetrical hyperplasia in Proteus Syndrome patients 
begins approximately a year after birth (112).  The bones of the limbs are particularly affected, 
with the hyperplasia altering normal bone patterning and potentially leading to immobility of 
joints, and/or bowing and rotation of the long bones.  There is also a high rate of premature death 
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(20%), which is typically due to venous thrombosis and pulmonary embolism.  Vascular 
abnormalities and tumors also occur (73, 112). 
Inactivating mutations in PTEN, a tumor suppressor gene involved in the PI3K-AKT 
pathway, had been suspected to cause Proteus Syndrome, and were recently shown to cause a 
similar condition known as SOLAMEN (Segmental Overgrowth, Lipomatosis, Arteriovenous 
Malformation, and Epidermal Nevus) syndrome (73, 113). The affected areas in SOLAMEN 
patients are nullizygous for PTEN, the result of inheriting a germline mutation in PTEN, and a de 
novo somatic mutation in the affected area.  Because PTEN inhibits activation of the AKT 
kinase, PTEN deficiency leads to over-activation of the PI3K-AKT signaling pathway in the 
affected areas, results in increased cell proliferation and reduced apoptosis (73, 113).   
Proteus and SOLAMEN Syndrome are caused by disruptions in the same signaling 
pathway.   Tissues affected by Proteus Syndrome harbor a missense mutation (c.49GàA, 
p.Glu17Lys) in AKT1 (73).  Western blots demonstrated an increase in phophorylated AKT1 in 
affected areas, which is indicative of over-activation of the PI3K-AKT pathway.  Thus, Proteus 
Syndrome patients are somatic mosaics with a gain-of-function mutation in AKT1 in their 
affected tissues and SOLAMEN Syndrome patients are somatic mosaics with loss of function in 
PTEN, leading to AKT activation (113). 
How does overactive AKT1 cause the skeletal phenotype?  The role of PI3K-AKT 
signaling in bone is controversial (114).  Most of the data are consistent with the pathway acting 
to promote hypertrophic differentiation of growth plate chondrocytes.  Over-activation of this 
pathway in mice through the conditional loss of PTEN activity leads to an overgrowth of the 
skeletal elements, caused by an accelerated rate of hypertrophic differentiation (114-117).  
Possible downstream effectors of the PI3K-AKT pathway in the growth plate include mTOR, 
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SOX9, IHH, RUNX2, as well as COL2A1 and proteoglycans.  While more work is necessary to 
define PI3K-AKT pathway function(s) in bone, it is clear that the role of AKT is primarily to 
promote endochondral ossification in both humans and mice (73, 114).  In Proteus Syndrome 
patients, the mutant protein has the ability to cause accelerated, disorganized bone growth in 
asymmetric patches, leading to the debilitating phenotype (112).  Inhibitors of AKT1 or some of 
the downstream effectors may offer potential therapeutic avenues. 
INPPL1 Mutations in Opsismodysplasia 
 Opsismodypslasia is an autosomal recessive skeletal disorder that results in delayed bone 
age, extreme shortening of the bones in the hands and the feet, and short long bones.  Other 
features include craniofacial anomalies and macrocephaly, with variable viability.  The growth 
plates are typically highly disorganized, and the number of hypertrophic chondrocytes is 
reduced.  Mutations in the inositol polyphosphate phosphatase-like 1 gene (INPPL1) cause 
opsismodysplasia (69, 70).  INPPL1 encodes SHIP2, which acts in the phophostidyl inositol 
signaling pathway (108).  SHIP2 catalyzes the reaction to form PI(3, 4)P2 from PI(3, 4, 5)P3.  
This reduces the amount of PI(3, 4, 5)P3 available as a secondary messenger, causing 
accumulation of PI(3, 4)P2.  PI(3, 4)P2 can act as a context-dependent secondary messenger 
affecting signaling by insulin, EGF and FGF (108).   
Mice with Inppl1 loss-of-function are resistant to obesity, smaller than their littermates, 
and have distinctive craniofacial abnormalities (118).  The skeletal phenotypes in these mutant 
mice are similar to those reported in opsismodysplasia patients.  Thus, these mice could be used 
to uncover the mechanistic details downstream of Inppl1 loss-of-function.  SHIP2 is thought to 
interact with the EGF and FGF signaling pathways (108, 119).  Loss of inppl1 in zebrafish leads 
to an over-activation and broader expression patterns of downstream effectors of the FGF 
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pathway (108, 120).  These observations support a role for INPPL1 in the inhibition of FGF 
signaling, which may explain the skeletal phenotype to some extent, should it mediate signaling 
downstream of FGFR3.  This also means that opsismodysplasia patients might benefit from the 
therapies being developed for achondroplasia patients, which are based on limiting the effects of 
overactive FGFR3.   
cAMP signaling and Acrodysostosis  
Mutations in effectors of cAMP-dependent signaling processes have been discovered in 
cases of acrodysostosis (14, 17, 71).  This disorder exhibits autosomal dominant inheritance, and 
has variable presentation that can affect the skeleton, nervous system, and/or endocrine systems 
(25, 26).   Patients typically present with midface hypoplasia, brachydactyly, spinal stenosis, and 
short stature.  Resistance to parathyroid hormone, thyrotropin, and occasionally the 
gonadotropins has been observed in acrodysostosis patients.  Males exhibit hypogonadism, and 
females can experience menstrual cycle disruption.  
The PTHRP receptor and many other hormone receptors critical for growth are coupled 
to G-proteins that activate adenylate cyclases, and generate the secondary messanger cyclic AMP 
(cAMP).  Thus, the strategy of sequencing genes that regulate signaling events downstream of G-
protein coupled receptors led to the discovery of mutations in the cyclic AMP-dependent 
regulatory subunit of protein kinase A (PRKAR1A) in acrodysostosis patients (17).  Mutations in 
PRKAR1A cause reduced PKA activity, and reduced phosphorylated CREB, a downstream 
effector of PKA signaling.  This is most likely due to defective binding of cAMP by the 
regulatory subunit, which renders it incapable of dissociating from the catalytic subunit, resulting 
in loss of function (25). 
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Mutations in cyclic AMP-specific phosphodiesterase 4D (PDE4D) also cause 
acrodysostosis (14, 71).  Mutations in PDE4D are thought to reduce the activity of the enzyme 
by acting as a dominant negative, interfering with PDE4D dimer function.  The loss of 
phosphodiesterase activity leads to an increase in cAMP levels and desensitization of the cAMP 
pathway in the affected tissues. 
After the genetic etiologies of acrodysostosis were uncovered, some potential genotype-
phenotype correlations have emerged (25, 26).  Hormone resistance is reported more often in 
patients with mutations in PRKAR1A than in individuals with PDE4D mutations.  Mutations in 
PDE4D appear to cause varied degrees of intellectual disability.  Mutations in PRKAR1A tend to 
have a more pronounced effect on adult stature.  All the patients with mutations in this gene have 
been reported to be <-2.5 SD below the mean height, while less severe growth insufficiency is 
associated with mutations in PDE4D.   The sample size is small, and there are exceptions in each 
group, but the emerging correlations may help predict the course of disease. 
FGFR2 and Bent Bone Dysplasia 
 The function of FGFR2 in skeletal development has emerged from studies of human 
patients.  Gain-of-function mutations in FGFR2 cause a number of craniosynostosis syndromes 
(7), while loss-of-function mutations are reported in patients with Lacrimoauriculodentodigital 
syndrome (LADD).  LADD patients are heterozygous for the mutation, indicating a 
haploinsufficiency disorder, and the skeletal defects mainly affect the digits.  Based on these 
studies, the skull and the digits appear to be the two components of the skeleton most sensitive to 
changes in signaling through FGFR2.     
FGFR2 mutations can also cause a perinatal lethal form of skeletal dysplasia, known as 
Bent Bone Dysplasia-FGFR2 type (72).  Aspects of the phenotype include bent long bones, 
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osteopenia, craniosynostosis, dysmorphic facies, poorly mineralized calvaria, hypoplasia of the 
clavicle and pubic bone, and prenatal teeth.  Hypertrophic chondrocytes in the growth plates of 
these patients were smaller than control hypertrophic chondrocytes.  Two different FGFR2 
missense mutations each substitute a charged amino acid for a hydrophobic amino acid within 
the transmembrane domain of the receptor.  Both of these substitutions are predicted to cause 
loss of a transmembrane domain.  Experiments support the conclusion that this mutation impairs 
receptor trafficking to the plasma membrane, leading to a reduction in activated ERK1/2.  Thus, 
loss of function of FGFR2 causes Bent Bone Dyplasia.  These cases demonstrate the requirement 
for FGFR2 signaling in the long bones of the more proximal elements of the appendicular 
skeleton and the skull.  
SMAD4 and Myhre Syndrome 
Mutations in a number of components of the TGFβ-BMP signaling pathway are 
associated with forms of skeletal dysplasia (7, 121).  Mutations in SMAD4, a co-mediator 
SMAD for the downstream effectors (R-SMADS) of TGFβ and BMP signaling, have been 
discovered in patients with Myhre syndrome.  First described in 1980, this dominant syndrome 
results in short stature, brachydactyly, muscular build, distinctive facies, thickened skin, and 
limited mobility of the joints (16, 122, 123).  Additional features are frequently reported, 
including deafness, cryptorchidism, intellectual disability, hypertension, heart defects and eye 
defects. 
Interestingly, all known mutations discovered in Myhre syndrome patients to date alter 
the same residue in SMAD4: Isoleucine 500 (16, 109, 124) (Table 1.2).  There is much 
speculation as to how mutations in this residue are affecting the function of this critical mediator 
of TGFβ-BMP signaling.  The mutations increase the level of phosphorylated SMAD2/3 and 
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SMAD1/5/8 in the nucleus, meaning that the mutant SMAD4 is likely capable of allowing 
nuclear entry of the SMAD complex (16).  SMAD4 is ubiquitinated on a nearby residue (16, 
109), and the mutations lead to a decrease in ubiquitinated SMAD4 (16).  Furthermore, the 
mutation affected the transcript levels of TGFβ and BMP target genes, lending support to the 
hypothesis that mutant SMAD4 is most likely capable of entering the nucleus, but is defective in 
modulating transcription of its target genes.  This could be due to the fact that the domain of 
SMAD4 that harbors the mutation, the MAD homology domain, contains two sites that associate 
with known receptor SMADS, SMAD2 and SMAD3 (109).  It is surmised that introduction of 
the various substitutions for the isoleucine residue would render one of these sites defective, 
hampering the ability of SMAD4 to bind to R-SMADS, which would affect the complex’s ability 
to act as a transcriptional mediator (109).  This could have profound, wide spread effects 
throughout the body, and further experiments are required to determine the molecular 
pathogenesis and specificity of SMAD4 mutations that cause this genetic disorder.   
 Some aspects of TGFβ and BMP signaling in the growth plate remain enigmatic.  More is 
known about BMP signaling than TGFβ signaling in this context.  Loss of BMP signaling affects 
hypertrophic differentiation, as growth plates from BMP-deficient animals exhibit reduced 
hypertrophic zones.  These pathways may also play a role in organizing the growth plate, which 
has been shown to be critical for proper skeletal growth (125).  In the context of Myhre 
syndrome, it is possible that the disruption of the R-SMAD-SMAD4 association affects the rates 
of proliferation and differentiation of chondrocytes in the growth plate, and/or the organization 
of the growth plate (125), leading to the short stature noted in Myhre syndrome patients.  Further 
molecular inquiries are necessary to determine if this is true. 
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Epigenetics: Mutations in Histone Acetyltransferase KAT6B/MYST4 Cause a Variety of 
Disorders 
 The modification of histones by chromatin modifying enzymes maintains cellular identity 
and regulates cell fate transitions during differentiation (126, 127).  These processes are 
important to ensure proper organogenesis and growth.  Chromatin modifying enzymes include 
histone methyltransferases, histone demethylases, histone acetyltransferases (HATs), histone 
deacetylases (HDACs), and enzymes that facilitate the phorphorylation and ubiquitination of 
histones (126-128).  HDAC4 has been shown to affect the skeleton (129, 130). 
Mutations in KAT6B, a member of the MYST family of histone acetyltransferases, cause 
two distinct disorders that affect skeletal growth (15, 80).  Mutations in the 3’ end of KAT6B 
have been reported in patients with Say-Barber-Biesecker-Young-Simpson (SBBYS) Sydrome, 
or Ohdo Syndrome.  This disorder causes intellectual disability and facial abnormalities, and 
distinct skeletal characteristics including hypoplastic or absent patellae, joint laxity, and 
abnormally long first digits.  These patients are heterozygous for de novo mutations near the end 
of the last exon of the gene, which encodes a RUNX2-binding domain (80).  RUNX2 is a 
homeodomain transcription factor that can regulate chondrocyte hypertrophy, and it is well 
known as the master regulator of osteoblast differentiation (1, 131).  Thus, the skeletal phenotype 
in these patients could be due to defects in either or both cell types present in the skeletal 
elements.   
Distinct loss of function mutations in KAT6B cause a related disorder known as 
genitopatellar syndrome (15).  This form of skeletal dysplasia is relatively rare.  The disorder 
encompasses intellectual disability, absence or hypoplasticity of the patellae, craniofacial 
abnormalities, and genital malformations.  The causative mutations are de novo indels that cause 
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frameshifts or nonsense mutations at the start of the last exon of KAT6B (15).  These mutant 
forms of KAT6B lack the transcriptional activation domain and the RUNX2 binding domain.  
The mutant transcript does not undergo nonsense-mediated decay, and it is possible that the 
mutations of this exon in SBBYS and Genitopatellar syndrome patients cause KAT6B to act as a 
dominant negative (15, 80).  If this hypothesis is correct, it may explain the more severe 
phenotypes seen in these latter two syndromes in comparison to a Noonan-like patient and a 
hypomorphic allele of Kat6b in the mouse (80, 132).  If mutant KAT6B is unable to acetylate 
histones, a logical potential therapy would be histone deacetylase (HDAC) inhibitors to 
counteract the loss of this function, provided the appropriate specificity could be achieved.  
Clearly, KAT6B is another example of a gene that can cause multiple skeletal disorders when 
mutated, and future studies will clarify this at the mechanistic level. 
Could Mutations in miRNAs Cause Severe Short Stature? 
Recently, the deletion of a miRNA cluster was associated with Feingold syndrome, a 
disorder that can involve multiple organ systems, but the skeleton is consistently affected (133).  
Short stature, microcephaly, and brachydactyly of the second and fifth digits of the hands, and 
brachysyndactyly of the toes are the hallmark skeletal anomalies associated with this syndrome.  
Previous work on human patients had mapped the interval to human chromosome 2p23-p24 
(134).  Subsequent analysis of human patients uncovered heterozygous mutations in MYCN, or 
N-myc, which encodes the helix-loop-helix transcription factor v-myc myelocytomatosis viral 
related oncogene (135).  Prior to these discoveries, a locus distal to human chromosome 13q14 
was hypothesized to be associated with Feingold syndrome (133), but evidence confirming a 
second locus was lacking (134, 136).  Five years later, a mouse lacking the miR-17~92 miRNA 
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locus had a homozygous phenotype that resembled Feingold Syndrome, and the human ortholog 
maps distal to 13q14 implicating it as a second locus (55). 
Genomic DNA from Feingold patients negative for mutations in MYCN were analyzed by 
comparative genomic hybridzation (CGH) arrays to screen for disease causing copy number 
variations.  These patients were heterozygous for microdeletions on human chromosome 
13q31.3, a region that segregated with the phenotype in two families, and encompassed the miR-
17~92 microRNA cluster (81).  There is mounting evidence that MYCN directly activates 
transcription of this microRNA cluster (81, 137-141).  The hemizygous loss of function of either 
MYCN or this miR cluster lead to very similar skeletal phenotypes in mouse and human (81, 142-
144).  An in depth molecular understanding of the mechanism underlying the roles of MYCN and 
this microRNA cluster in the pathophysiology of Feingold Syndrome will include defining the 
targets of these microRNAs.  Discovering the essential role of miR-17~92 in skeletal 
development begs the question of whether other noncoding RNA mutations may cause skeletal 
dysplasia or other types of severe short stature. 
The Primordial Dwarfisms 
 Many of the skeletal dysplasias are characterized by disproportionate bone growth, with 
long bones being the most affected (2, 145).  Skeletal dysplasia patients also tend to have 
relatively normal-sized heads.  Primordial dwarfism, on the other hand, causes a proportionate 
reduction in growth, similar to that caused by deficiencies in insulin-like growth factor 1 (IGF-1) 
or growth hormone (GH), both of which lead to proportionate short stature (145).  Patients with 
IGF-1 deficiency and primordial dwarfism are smaller at birth, and are sometimes ascertained in 
utero, while GH deficiency is not manifested until later in life.  Primordial dwarfism patients 
differ from most skeletal dysplasia patients in that they have a proportionate reduction in skull 
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size or microcephaly.  Primordial dwarfism patients have severe short stature, with some 
reaching only 1 meter as adults.   
The primordial dwarfisms’ phenotypic resemblance to GH/IGF-1 deficiency challenges 
the current classification of disorders of skeletal growth.  GH/IGF-1-deficient patients do not 
have skeletal dysplasia.  Their defects are systemic in nature, rather than local, as is the case with 
achondroplasia patients (7).  In addition, many growth defects attributable to GH/IGF-1 
deficiency are treatable with supplementation, resulting a normal adult target height (146).  This 
is not the case for traditional skeletal dysplasia patients (2).  Therefore, the primordial dwarfisms 
represent an interesting genetic and physiological state.  Causative mutations uncovered to date 
regulate overall cell number, but do not affect endocrine processes (145).  It is not clear whether 
the differences in cell number are due to augmentation of cell death, a delay or reduction in cell 
proliferation, or both.  Mouse models and cell culture studies should clarify these genes’ roles in 
cases of primordial dwarfism. 
There are several disorders that fall into the primordial dwarfism category: Seckel 
syndrome, Meier-Gorlin Syndrome, and microcephalic osteodysplastic primordial dwarfism I-III 
(MOPD I-III).  A review of these disorders was recently published (145).  We provide an 
abbreviated description of each disorder below. 
There are differences in the severity of various aspects of the phenotype in each of these 
conditions (145).  Seckel syndrome patients tend to have moderate to mild intellectual disability, 
microcephaly, and distinctive facies.  MOPD I/III causes curvature of the long bones, drastic 
growth insufficiency, and early death by three years of age.  This disorder also leads to skin 
abnormalities and sparseness of hair.  MOPD II is compatible with life, and patients have normal 
intellect.  They have a predisposition to developing vascular abnormalities and insulin resistance, 
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which can lead to type II diabetes.  Meier-Gorlin syndrome causes hypoplasia or complete 
absence of the patellae, microtia, microcephaly, and can result in short stature, but the effect on 
growth is highly variable from patient to patient (147, 148).  These characteristics are listed in 
Table 1.3. 
Sequencing genomic DNA samples from patients with primordial dwarfism have yielded 
genetic aberrations in genes with diverse functions that are expected to affect all of the cells in  
the body (145) (Table 1.3).  Seckel syndrome is associated with mutations in the DNA-damage 
response genes ATR (149), ATRIP (83), and RBBP8 (86), as well as the centriole-associated 
genes CPAP (CENPJ) (151) and CEP152 (150).  MOPD II is caused by mutations in PCNT, a 
gene that encodes a pericentriolar protein involved in the generation of the mitotic spindle and 
centrosome maturation.  Recently, a novel form of microcephalic primordial dwarfism has been 
associated with mutations in NIN, the gene that encodes another centrosomal protein ninein (58).  
Little is known about the function of ninein, although it is thought to be important in the 
Table 1.3 Genetic Causes of the Primordial Dwarfisms 
Gene Category Genes Involved Form of Primordial 
Dwarfism 
Features 




Seckel Syndrome Moderate learning disability 




 (88, 89, 148) 
ORC4 
 (87, 89, 148) 
ORC6 (89, 148) 
CDT1 (89, 148) 





Growth Variably Affected  





POC1A (59, 60) 
ORC1  














MOPD I Severe Pleiotropic Phenotypes 
Neonatal Lethality 
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regulation of asymmetric cell division (154-156).  Additionally, mutations in genes that encode 
components of the origin recognition complex (ORC), which regulates the licensing of DNA 
replication origins, are the cause of Meier-Gorlin Syndrome (87-89, 148) (Table 1.2 and 1.3).  
Finally, MOPD I has been shown to be caused by mutations in U4ATAC, which is involved in 
the splicing of U12 introns, a minor subset of introns present in a distinct grouping of genes in 
the human genome (91, 92).  Many of the genes that contain this type of intron are involved in 
the processes highlighted above, and it is thought that the primordial dwarfism phenotype in 
MOPD II is due to alterations in the splicing of specific transcripts that are required for proper 
modulation of cellular growth and cell number (145).  
Clearly, genes that encode DNA repair components, centrosomal proteins, and genes 
involved in DNA replication have profound impacts on human growth when they are disrupted.  
Genes within these categories should be considered as likely candidates in patients with novel 
forms of primordial dwarfism or without mutations in the genes that have been previously 
mentioned.  Also, while a number of cellular processes are represented in these primordial 
dwarfism-associated genes, one common theme is clear—these are all genes that feed into the  
regulation of the cell cycle (Figure 1.3).  
The phenotypes of individuals with primordial dwarfisms generally fall into two classes 
that correspond with the two major types of genes involved: DNA repair and replication or 
centrosome associated proteins.  MOPD I is an exception, as the mutation in U4ATAC likely 
disrupts a number of cellular functions, causing pleiotropic effects and early lethality.  Mutations 
in ATR and CEP152 in Seckel syndrome patients cause similar phenotypes—moderate learning 
disability and a more marked reduction in the size of the skull as opposed to an overall decrease 
in height.  In contrast, patients with mutations in CENPJ (CPAP) have clinical features similar to  
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Figure 1.3.  Cellular pathways disrupted in primordial dwarfism.  Most genes implicated in 
primordial dwarfism [microcephalic osteodysplastic primordial dwarfism (MOPD) I/II, Seckel 
Syndrome, Meier-Gorlin Syndrome (MGS), Short stature, Onychodysplasia, Facial 
dysmorphism, and Hypotrichosis (SOFT) Syndrome] are involved in cell cycle regulation and 
cell division.  These processes include: primary ciliogenesis (G1 phase), DNA replication and 
centrosome duplication (S phase), DNA Repair and centrosome maturation (G2 phase) and 
mitotic spindle formation (M phase).  Many of the genes function in more than one phase of the 
cell cycle.  Some genes affect the rate of progression through the cell cycle, and some lead to 
aneuploidy, probably because of defects in DNA repair or mitotic spindle formation.  In some 
cases the cell cycle becomes disrupted after several rounds of cell division, due to disturbances in 
centriole duplication and/or maturation.  All the processes listed involve replication and repair or 
maturation of the genome and the centrosome, except RNU4ATAC, but its critical role in splicing 
could disrupt one or more genes involved in cell cycle regulation or division. 
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MOPD II patients with mutations in PCNT, in that both groups of patients have a proportionate 
reduction in head size and body size.  Intellectual disability in the Seckel CENPJ patients is mild, 
while MOPD II/PCNT patients have a normal intellect.  ORC-associated proteins such as ORC1 
associate with the centrosome (157, 158), and mutations in ORC1 cause more severe reductions 
in height and head circumference than any other cause of Meier-Gorlin syndrome  (148, 158).  
All but one of these ORC1 patients had normal intellect, and the one exception had mild 
intellectual disability.  
Mutations in genes affecting centrosome biology apparently cause more severe dwarfism 
than genes involved in DNA repair and replication.  Conversely, genes involved in DNA repair 
and replication tend to have a greater impact on intellectual development and size of the brain 
and skull.  The effect of the centrosomal-associated genes on stature may be due to the 
requirement of the centrosome to form the primary cilium, a structure required to maintain the 
organization of the growth plate (4, 5, 9).  There are exceptions to these general correlations 
between clinical features and the type of gene mutated.  For example, mutations in the 
centrosomal protein encoded by NIN cause both severe short stature and profound intellecutal 
disability (58).  Morpholino-induced knock down of NIN in zebrafish or loss of ninein in mice 
reduces the number of cells in a distinct part of the developing nervous system (154).  While 
NIN deficiency does not appear to impact overall cell division, it could affect asymmetric 
divisions required for specific populations of cells, and it could have important undiscovered 
functions distinct from its role in centrosome biology 
The mechanistic underpinnings of Meier-Gorlin syndrome have begun to emerge from 
studies on ORC1.  ORC1 binds dimethylated lysine 20 of histone H4 (H4K20me2), a chromatin 
modification commonly present at replication origins, and mutations in the binding domain cause 
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Meier-Gorlin syndrome (159).    Loss of the H4K20me2 binding domain is associated with 
reduced ORC1 at replication origins, presumably leading to disrupted cell cycle progression.   In 
contrast, in vitro studies suggest that slow progression through S-phase is not a determinant of 
the MGS phenotype (160).  The generation and analysis of mouse models could clarify the role 
of cell cycle and cell number on the MGS phenotype. 
ORC1 is linked to the regulation of centrosome duplication, an event that is triggered by 
cyclin E-CDK2 activity (158, 161).   ORC1 mediated inhibition of cyclin E-CDK2 is defective in 
specific ORC1 mutants (R105Q and E127G).  These mutated residues are located on the surface 
of the H4K20me2 binding domain, which is hypothesized to confer differential binding to 
cyclins A and E.  These mutations cause centrosome reduplication/amplification in transfected 
cells, likely though a failure to inhibit cyclin E/CDK activity.  
MGS-associated mutations in ORC1 profoundly reduce the rate of primary cilium 
formation and alter the collection of signaling components present within the cilium (160).  Cilia 
that do form have a normal appearance.  Meier-Gorlin Syndrome and related forms of primordial 
dwarfism could be considered as ciliopathies.   
The multiple functions of ORC1 explain the pleiotropic features of Meier-Gorlin 
syndrome patients.  Future work will clarify the complex functions of this gene and may identify 
mutations in other members of the Origin Recognition Complex that cause primordial dwarfism.  
The Skeletal Ciliopathies  
Mutations in components of the centrosome in primordial dwarfisms could influence the 
formation and maintenance of the primary cilium (160).  The primary cilium is involved in 
maintaining the ornate architecture of the growth plate (5), and disruptions in ciliogenesis can 
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lead to the development of many severe forms of skeletal dysplasia (9).  These conditions are 
known as the skeletal ciliopathies, which may include primordial dwarfisms (160). 
The term skeletal ciliopathy refers to skeletal dysplasias that are caused by mutations in 
genes that encode components of the primary cilium or its regulation (9).  Some of these skeletal 
ciliopathies spare the tissues typically damaged in ciliopathies such as kidney, retina, brain, and 
liver.  Many skeletal ciliopathies are embryonic or perinatal lethal, and many of them result in 
short ribs and polydactyly, presumably due to altered IHH signaling.  The short ribs may impair 
lung development and function, causing lethality at birth (10, 57). 
The primary cilium is a microtubule-based structure present on the majority of non-
cycling cell types, including chondrocytes.  The axoneme of this non-motile cilium extends 
outward from the basal body, the foundation of the cilium generated by the mother centriole of 
the centrosome (162) (Figure 1.4).  Sheathed in plasma membrane and decorated with numerous 
receptors and channels, the primary cilium serves as a major signaling center, particularly for the 
Hedgehog and Wnt signaling pathways (163).  Due to the importance of IHH signaling in the 
growth plate, it is clear that perturbation of the primary cilium or the trafficking of necessary 
signaling components have the potential to disrupt skeletal growth.     
The primary cilium maintains growth plate architecture and organization and is thought 
to regulate cellular positioning in the growth plate (5).  Chondrocytes typically divide 
perpendicular to the plane of the growth plate, and slide back over one another to form the highly 
ordered columns in the proliferative zone.  This process, known as chondrocyte rotation (5), is 
regulated by Wnt signaling and the planar-cell polarity pathway (4, 6).  Mouse models of skeletal 
ciliopathies have disorganized growth plates that underlie the growth insufficiency.  The 
disorganized growth plate may arise from perturbation of cell polarity (Wnt), and the rate of  
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Figure 1.4. The primary cilium.  The primary cilium is a structure present on most cell types, 
including chondrocytes.  In the growth plate, the primary cilium serves to maintain growth plate 
organization, presumably as a center for signaling pathways such as the WNT/Planar Cell 
Polarity pathway and IHH.  The primary cilium is a microtubule-based structure that extends out 
from the mother centriole of the centrosome.  The mother centriole forms the basal body, the 
foundation of the ciliary axoneme.  The cell membrane wraps around the cilium, and numerous 
motor proteins and cargo-binding proteins allow for proper transport of components into and out 
of the cilum by intraflagellar transport (IFT).  The ciliary pocket is a depression in the cell 
membrane near the basal body, and the transition zone is the area between the basal body and the 
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growth plate chondrocyte proliferation and hypertrophic differentiation (IHH).  Loss of these 
critical mechanisms could lead to short stature in affected animals and human skeletal ciliopathy 
patients.  Ciliary genes comprise a large and growing family (9).  Many regulate intraflagellar 
transport (IFT), the mechanism responsible for trafficking components into the cilium (IFT 
complex B, anterograde trafficking) or out of the cilium (IFT complex A, retrograde trafficking) 
(Figure 1.5).  Kinesin motors carry IFT-B components, while dynein motors carry IFT-A 
components.  This trafficking system ensures that the cilium is maintained, lengthened, and that 
receptors and downstream effectors of signaling pathways are targeted properly to the cilium.  A 
number of mutations in the genes that encode these proteins cause skeletal ciliopathies (Figure 
1.5).  Mutations in genes affiliated with the basal body (Figure 1.5) could cause disruptions in 
primary cilium formation and maintenance, or affect mitotic spindle formation and orientation.  
Mutations in these genes may interfere with completion of cell division, and/or impact the plane 
of division affecting chondrocyte rotation and stacking.   
 Mutations in NEK1, a basal body-associated component of the cilium, cause Short-Rib 
Polydactyly Syndrome Type Majewski (67).   The NEK kinases (never-in-mitosis gene a-related 
kinases) constitute a large gene family composed of eleven members (NEK1-NEK11) (164).  
NEKs regulate microtubule dynamics, cell cycle progression and ciliogenesis.  Mutations in 
other NEK genes may cause skeletal dysplasia (including, but not limited to, primordial 
dwarfisms), classical ciliopathies, or cancer.  Moreover, all gene families encoding cilia-
associated proteins, including NEK, CEP, WDR and TMEM, are excellent candidates for human 
disease genes and worthy of functional analysis in model organisms.   
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Figure 1.5. Primary cilia proteins implicated in skeletal dysplasias.  Components of the 
primary cilium are disrupted in many different forms of skeletal dysplasia.  These include genes 
that encode parts of motor proteins (dynein), and parts of both the IFT-A complex and IFT-B 
complex, which regulate retrograde and anterograde ciliary trafficking, respectively.  The colors 
of the cilium components signify the forms of skeletal dysplasia with which they are associated. 
*IFT121 has been shown to cause SRP type V in addition to Sensenbrenner syndrome (9) 
 
A Missing Link: Mutations in POC1A Cause a Novel Form of Primordial Dwarfism That 
Exhibits Defects in the Primary Cilium 
 The newest member of the skeletal ciliopathy group is a novel form of primordial 
dwarfism caused by mutations in the gene POC1A, which encodes protein of centriole 1A.  
Patients are smaller than average size in utero, and remain so throughout their lives (59, 60).  
Two homozygous mutations were found in highly consanguineous families: a premature stop 
codon (R81X) (60), and a missense mutation (L171P) (59).  Surprisingly, the premature stop 
codon undergoes efficient read-through in patient fibroblast cultures, and POC1A protein levels 
are only reduced 15-50% (60).  The fibroblasts have abnormal mitotic spindle orientation, form 
multipolar spindles, and have multiple centrosomes in non-cycling cells.  The frequency of 
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missense mutation is a non-conservative change, but the protein may retain some functions.  
Fibroblasts from these patients have more centrosomes and exhibit alterations in cholera toxin 
trafficking (59).  POC1A protein misfolding could create ER and/or Golgi stress that contributes 
to the phenotype, although the clinical features appear similar in both families.    
 The effects both mutations have on cilia and centrosomes may be sufficient to produce 
the growth insufficiency.  Two lines of evidence support this idea.  First, knock down of both 
POC1A and the related POC1B gene in HeLa cells alters the orientation of the mitotic spindle, 
causing unequal bipolar, monopolar, or even multipolar spindles (165).  These knockdowns 
cause failure of daughter centrioles to mature into new mother centrioles, which may lead to the 
disruption in mitotic spindle formation.  The lack of mother centrioles could affect the cells’ 
abilities to form primary cilia, as the mother centriole is responsible for the formation of the 
basal body and the extension of the ciliary axoneme (162).  This could lead to profound effects 
on growth plate organization and signaling (5, 163), leading to severe short stature.   Secondly, 
mutations in POC1A, ORC1, CENPJ, and PCNT cause very similar growth deficiencies and 
microcephaly, and all of these genes encode proteins associated with the centrosome (151-153, 
158, 160, 165).   
 It will be interesting to determine whether defects in the other primordial dwarfism genes 
cause the cilia defects similar to those observed in cells from POC1A patients, or whether, like 
ORC1 mutations, the cells form relatively normal cilia, but at a slower rate (160).  Genetically 
engineered mice that model these diseases could be a source of primary fibroblasts or bone cells 
for functional studies.  In addition, they could be used to determine which of these genes cause 
disorganization of the growth plate.  This type of study would clarify the roles of these genes in 
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the cause of postnatal growth retardation in this subset of primordial dwarfism patients, which 
may be considered as skeletal ciliopathy patients. 
Novel Skeletal Disorders of Unknown Etiology 
While the genetic causes of the over 450 forms of skeletal disorders (8) are being 
uncovered at a rapidly expanding rate, there are still distinct skeletal disorders being discovered 
that have no known genetic etiology.  Eleven novel skeletal disorders have been reported since 
2010 (Table 1.4).  While many are not named, some of their features resemble previously 
described forms of skeletal dysplasia, suggesting that mutations in known genes could be 
responsible.  It is likely that some are caused by mutations in novel genes important for normal 
skeletal growth and development.   
Given the high degree of genetic heterogeneity already evident for this group of growth 
disorders, the best strategy for identifying the genetic etiology in a new patient may be to 
conduct exome sequencing or genome sequencing.  In some cases the utilization of high-
throughput genotyping strategies could map the loci, facilitating the analysis of variants.  The 
temporal gap between the description of a particular patient phenotype and uncovering the 
genetic etiology is becoming narrower and narrower. 
Future Directions: How Mutation Discovery Advances Skeletal Dysplasia Research 
 Geneticist's contributions to understanding skeletal dysplasia begin by assigning a gene to 
a disorder and extend to understanding the pathophysiology of the disease and development of 
treatments.  Receiving a molecular diagnosis often gives patients and their families relief because 
they can understand the cause, the progression of disease over a lifetime, and the risk for future 
pregnancies.  Human disease gene discovery is a starting point for understanding the normal 
regulation of skeletal growth and for studying development in model systems.  Mouse models for  
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Table	  1.4	  Novel	  Skeletal	  Disorders	  	  
Name	   #	  Pts	   Inheritance	   Onset	  of	  
Growth	  
Delay	  
Skeletal	  Features	   Other	  Features	   Similarity	  to	  Other	  SD	   Gene/Locus	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human skeletal dysplasias and chondrocyte cell lines have been invaluable for mechanistic 
insight that explains the clinical features of many skeletal dysplasia phenotypes at the molecular 
level.  This insight is a foundation for developing and testing therapeutic interventions, 
completing the circle of bedside to bench and back to the bedside. 
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Achondroplasia remains one of the best examples of how the discovery of a mutation can 
lead to the discovery of potential therapies in less than 20 years.  Interestingly, the discovery of 
mutations in NPR2 in AMDM patients (107) has helped shape the trajectory of this area of 
research.  Work in cell culture and mouse models has revealed that the genetic and molecular 
etiologies of both disorders are intertwined with one another.  Activation of NPR2 inhibits 
FGFR3-mediated activation of the MEK/ERK MAPK pathway (103), which allows the growth 
plate to promote chondrocyte differentiation.  Loss of CNP-NPR2 mediated inhibition of FGF 
signaling in a mouse model of AMDM leads to over activation of the MEK/ERK MAPK 
pathway (102), and treatment of chondrocytes with CNP leads to reduced ERK activation (103). 
Treating achondroplasia patients with CNP, the ligand for NPR2, was a rational therapy based on 
knowledge of the effect of the FGF mutation on MEK/ERK and the oppositional effects of CNP 
signaling.  This therapy is somewhat successful in mouse models with various methods of 
continuous administration (96, 104, 106).  Parathyroid hormone (PTH) (97), FGFR3 inhibitors 
(98, 99), and CNP analogs (100) are all being explored as potential treatments for 
achondroplasia.  Finally, the administration of MEK/ERK inhibitors has been postulated to be a 
method of intervention in mouse models of Apert syndrome (gain-of-function mutation in 
FGFR2) (101), and AMDM (102).  While these modes of therapy are still under development, it 
is promising that targeting these pathways has improved growth in vitro and in vivo.  Future 
research will involve identifying additional compounds that modulate this interconnected 
signaling network, potentially with greater specificity, and improved delivery of therapeutics to 
the growth plate.  Lastly, the progression from mutation discovery to the development of 
therapies in this case should serve as a model for researchers to follow when considering the 
testing and development of treatments for the other forms of skeletal dysplasia. 
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Skeletal Dysplasia Mutations Further Our Understanding of Height Variation 
 Do mutations uncovered in skeletal dysplasia patients provide any information about 
height variation in the human population?  The answer to that question is probably 
"yes" because some skeletal dysplasia-associated genes have been implicated in human height.  
A genome-wide association study (GWAS) conducted on human height variation (177) reported 
21 of 241 genes (8.7%) known to cause a human growth disorder in their height-associated 
genomic loci, including genes influencing the endocrine system and skeleton.  An important next 
step is to identify functional variants in the candidate genes.  In any case, the GWAS studies 
explain only a small portion of the known heritability of height variation in humans.  It is likely 
that genetic interactions contribute a great deal to the missing heritability.   The known skeletal 
dysplasia genes implicate several pathways, and it is likely that multiple hits in a pathway could 
have synergistic effects. 
Concluding Remarks 
 In the past two years remarkable progress has been made in understanding skeletal 
dysplasia.  Forty-one new genetic causes have been uncovered (Table 1.2), and eleven novel 
skeletal growth disorders have been reported (Table 1.4).  The speed and volume in which these 
discoveries are being made leads us to propose the generation of a Nosology and Classification 
of Skeletal Disorders Database, where researchers could ask for information to be uploaded as it 
is discovered.   Such a database could be expanded to include all types of growth disorders, 
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CHAPTER 2 
A Novel Loss-of-Function Mutation in Npr2 Clarifies Primary Role in Female 
Reproduction and Reveals a Potential Therapy for Acromesomelic Dysplasia, Maroteaux 
Type 
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Abstract 
 We discovered a new spontaneous mutant allele of Npr2 named peewee (pwe) that 
exhibits severe disproportionate dwarfism and female infertility.  The pwe phenotype is caused 
by a 4 base-pair deletion in exon three that generates a premature stop codon at codon 313 
(L313X).  The Npr2pwe/pwe mouse is a model for the human skeletal dysplasia acromesomelic 
dysplasia, Maroteaux type (AMDM).  We conducted a thorough analysis of the female 
reproductive tract and report that the primary cause of Npr2pwe/pwe female infertility is premature 
oocyte meiotic resumption, while the pituitary and uterus appear normal.  Npr2 is expressed in 
chondrocytes and osteoblasts.  We determined that loss of Npr2 causes a reduction in the 
hypertrophic and proliferative zones of the growth plate but mineralization of skeletal elements 
is normal.  Mutant tibiae have increased levels of the activated form of ERK1/2, consistent with 
the idea that NPR2 signaling inhibits the activation of the MEK/ERK MAPK pathway.
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Treatment of fetal tibiae explants with MEK1/2 inhibitors U0126 and PD325901 rescues the 
Npr2pwe/pwe growth defect, providing a promising foundation for skeletal dysplasia therapeutics. 
Introduction 
 
Disruptions in skeletal development and growth are classified as skeletal dysplasias and 
are an important contributor to severe short stature, occurring in approximately 1 out of every 
5000 births (1).  The effects on individuals with skeletal dysplasia can range from relatively 
minor to lethality (1-3) and multiple organ systems can be affected (1).  The advent and 
improved accessibility to high-throughput sequencing technologies has brought forth a wealth of 
information regarding the genetic causes of skeletal dysplasias (1, 4).  According to the most 
recent nosology, there are 456 forms of skeletal dysplasia, of which 316 have been associated 
with mutations in one or more of 226 genes (4).  This means that approximately 70% of the 
skeletal dysplasias have known genetic causes (4).  The genetic causes of the remaining forms 
are currently unknown (1, 3, 4), and even those forms that have a known genetic cause may not 
have a clear molecular mechanism (1).  Animal models of skeletal dysplasia have been useful in 
understanding the mechanisms by which these genes regulate proper skeletal development and 
growth and contribute to the pathology of skeletal dysplasia (1, 5-7).  
Some disorders of the skeleton also affect the reproductive organs (8-11).  Infertility is 
estimated to affect 15% of the global population and 25% of these cases are idiopathic (12).  
There has been a surge of interest in the mechanisms of female infertility and sub-fertility with 
respect to reproductive aging, as many women in developed countries are delaying their age of 
first conception past their early 20s, when female fertility is at its zenith (13).  Mouse models of 
female infertility have offered much in the way of understanding the genetic regulation of female 
fertility (14, 15). 
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We have discovered a novel recessive, mutant allele of Npr2, the gene that encodes 
natriuretic peptide receptor type 2 (NPR2), that we have named peewee (pwe).   The mutant mice 
have growth insufficiency, skeletal dysplasia, and female infertility.  Mutations in NPR2 cause a 
rare form of recessive skeletal dysplasia in humans, Acromesomelic Dysplasia, Maroteaux Type 
(AMDM) (16), which affects the middle and distal portions of limbs and the shape of vertebrae 
(16, 17).  Npr2 encodes a membrane-bound guanylyl cyclase that generates the secondary 
messenger cyclic GMP upon binding its ligand, C-Type natriuretic peptide (CNP) (18). 
We report a comprehensive analysis of the role of Npr2 in the regulation of female 
fertility, and evidence that pharmacological inhibition of MEK1/2 is sufficient to rescue the 
peewee growth defect in tibial explants.  These findings offer promising clues as to signaling 
pathways that could be therapeutic targets in the treatment of AMDM and other forms of skeletal 
dysplasia. 
Results 
 The peewee Growth Defect 
 The peewee (pwe) mouse arose on the NAW/WI background, was outcrossed to obtain 
hybrid vigor, and was maintained as a stock by breeding heterozygotes.  Only 12% of the 
progeny were mutant, which is lower than expected for autosomal recessive inheritance.  
Outcrossing to Mus castaneus supported homozygote viability.  Mutants constituted 27% of the 
progeny of this F1 x F1 intercross (28/103), consistent with the expected Mendelian ratio for an 
autosomal recessive allele. 
pwe homozygous mutants exhibit growth delay and disproportionate dwarfism that is 
evident at two weeks of age (Figure 2.1).  Body weight and crown-rump length of mutants are  
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Figure 2.1. Decreased body size and growth delay in peewee mice.  Panel A: Comparison of 
an unaffected littermate and a peewee mutant reveal decreased body size and cranial 
dysmorphology by 2 weeks of age (P14).  Panel B: Growth curve (unaffected males: open 
squares, unaffected females: open circles; affected males: closed squares; affected females: 
closed circles) showing significant decrease in body weight in mutants by P14.  Arrows below 
indicate range of ages at vaginal opening in unaffected (dashed arrow, n=11) and affected (solid 
arrow, n=6) females. 
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54% and 77%, respectively, of their unaffected littermates (Table 2.1).  pwe mice have a 
characteristic cranial dysmorphology that includes a domed skull and short snout (Figure 2.1A).  
Malocclusion is frequent, but incompletely penetrant.  All bones formed through endochondral 
ossification are significantly reduced in length (Table 2.1 and Figure 2.2A, Panels A-L). 
Table 2.1. Disproportionate Dwarfism in peewee Mutants 
 unaffected  peewee  ratio1  p-value 
body weight (g) 25±1 16±1 0.54 0.001 
Length of body and skeletal elements (mm)2 
crown to rump 71.05±0.96 54.43±0.94 0.77 0.0003 
radius 10.40±0.19 5.28±0.13 0.51 <0.0001 
ulna 12.83±0.25 7.16±0.18 0.56 <0.0001 
femur 15.12±0.19 8.49±0.21 0.56 <0.0001 
humerus 11.52±0.17  7.36±0.17 0.64 <0.0001 
tibia 15.84±1.01 10.28±0.29 0.65 0.001 
illium 17.09±0.39  12.59±0.13 0.74 <0.0001 
scapula 10.93±0.15 8.22±0.15 0.75 <0.0001 
skull 23.38±0.31 19.89±0.41 0.85 0.0003 
Width of skeletal elements (mm) 2 
L6 vertebrae 3.51±0.09 2.48±0.08 0.71 0.001 
femur3 (a) 2.08±0.04 1.83±0.03 0.88 0.0005 
femur3 (b)  1.47±0.04  1.36±0.04 0.93 NS 
skull 11.52±0.22 11.28±0.35 0.98 NS 
rib 0.78±0.05 0.83±0.03 1.06 NS 
1Ratio of peewee to unaffected  
2Individual skeletal elements are listed from most affected to least affected 
3Femurs were measured in the thicker (a) and thinner (b) dimensions 
 
The proximal skeletal elements of the appendicular skeleton (femur and humerus) are the 
most severely affected in the pwe mouse (Table 2.1 and Figure 2.2A, Panels C and E).  All 
skeletal elements formed through endochondral ossification are ≤ 75% the length of unaffected 
skeletal elements (Table 2.1 and Figure 2.2A, Panels A-L).  There is no reduction in the width of 
the skull, femur (thinner dimension) or ribs (Table 2.1).  A fully penetrant aspect of the 
phenotype is a notch on the dorsal surface of the atlas (Figure 2.2A, Panel K).   
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Figure 2.2.  Skeletal phenotype of peewee mice.  Panel A: Whole skeletal preparations 
individual skeletal elements from mutants and normal littermates.  Unaffected (A.) and affected 
whole skeletons (B.) are shown.  Individual skeletal elements from unaffected and affected 
animals were dissected from whole skeletons (C.-L.).  K: C2, or the atlas: Mutant C2 vertebrae 
have an abnormal notch on the dorsal side.  Panel B: Bone histology.  Sections through 5-week 
old male proximal tibiae at the level of the growth plate (40X Magnification).  Arrows indicate 
hypertrophic (H), proliferative (P) and resting zones (R).   
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Sections through 5-week old male tibial growth plates suggest that the skeletal growth 
defect in pwe mice stems from a disruption in the regulation of chondrocyte differentiation, and  
potentially proliferation, due to the reduction in the height of the hypertrophic and proliferative 
zones of the growth plate (Figure 2.2B).  However, all zones of the growth plate are present, and 
their organization is maintained, meaning that the disturbance in skeletal growth may be due to a 
disruption in the number or rate in which the chondrocytes progress through the zones of the 
growth plate (Figure 2.2B).  
Molecular Identification of the peewee mutation 
 Analysis of DNA samples from fifteen affected animals from a [(pwe/+) X CAST/Ei+/+] 
F1 X F1 intercross with a SNP mapping panel (19) placed the locus in a region on proximal 
mouse chromosome 4.  Analysis of additional animals with more markers confirmed this 
location and narrowed the interval.  The genotype of affected mice placed the mutation distal to 
the microsatellite marker D4Mit93 (Figure 2.3A), and analysis of unaffected animals narrowed 
the critical interval to a 3 Mb region between D4Mit212 and D4Mit109 (Figure 2.3A, 1 animal 
per marker), that contains more than 80 genes and corresponds to human chromosome 9p13.3.  A 
search for skeletal dysplasias associated with this region of human chromosome 9 identified 
Acromesomelic Dysplasia, Maroteaux Type, which is caused by loss-of-function mutations of 
Npr2 in humans (16, 17).  Sequencing of Npr2 in known pwe mutants revealed a four base-pair 
deletion in exon 3 of Npr2 (Figure 2.3B).  This deletion results in a frameshift that generates a 
premature stop codon at codon 313, which encodes a leucine residue in the wild type and 
reference open reading frame (ORF) (L313X, Figure 2.3B).  Genotyping this mutation revealed 
that one apparently affected animal was actually a runted heterozygote, explaining the erroneous 
exclusion of Npr2 as a potential candidate gene early in our analysis (Figure 2.3A, asterisk). 
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Figure 2.3.  The peewee phenotype is caused by a mutation in Npr2.  Panel A. Mapping of the 
peewee critical interval in progeny of an F1 X F1 cross with Mus castaneus.  Haplotypes are 
shown for selected mice, and genotypes indicating homozygous or heterozygous Mus castaneus 
alleles are open boxes, homozygous peewee stock are black boxes, and gray boxes indicate data 
are unavailable.  The critical interval is limited to the region between D4MIT212 and D4MIT109.  
A single animal that appeared affected genotypes as a heterozygote in the critical interval (*).  
Panel B: DNA sequencing of genomic DNA reveals that peewee animals have a 4 bp deletion in 
exon 3 of Npr2.  This generates a premature stop codon at codon 313 (L313X).  Panel C: 
Missense and nonsense mutations (true nonsense and those formed from frame shift mutations) 
in NPR2 are found in AMDM patients (16, 20-22), spontaneous mutant Npr2slw/slw and Npr2cn/cn 
mice (23-25), and a targeted knock out (KO) animal (26).  (TMD: Transmembrane domain, 
CCD: Coiled-coil domain) 
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Npr2 encodes a membrane-bound guanylyl cyclase that is present at the plasma 
membrane as a dimer (18).  Mutations in human AMDM patients occur throughout the length of 
the encoded NPR2 protein (16, 21) (Figure 2.3C).  The premature stop codon at codon 313 in 
Npr2pwe/pwe mice truncates NPR2 within the ligand-binding domain (18) (Figure 2.3C).  Without 
an intact ligand binding domain or any of the domains C-terminal to the premature stop codon, 
any translated protein from the pwe allele is predicted to be non-functional, generating a null 
allele (Figure 2.3C).  The growth insufficiency of pwe mutants is indistinguishable from that 
reported for other mouse null alleles of Npr2 (23-26).   
Npr2pwe/pwe Female Infertility 
We tested fertility by mating wild-type mice with Npr2pwe/pwe mutants.  Males were sub-
fertile, but had no obvious abnormalities in the penian bone or testis histology (data not shown).  
Over a three-month period, all unaffected females (n=3) bore litters, while none of the 
Npr2pwe/pwe females (n=3) bore litters (data not shown).  Npr2 is expressed at all levels of the 
female reproductive tract in the rodent (18, 27-30).  Thus, Npr2pwe/pwe female infertility could be 
due to defects in any or all of these organs.  We undertook a systematic approach to uncover 
critical sites of Npr2 action in the female reproductive tract. 
We tested whether Npr2pwe/pwe females experienced puberty normally by observing the 
date of vaginal opening as an indicator of the onset of puberty in mice (31-33).  The control 
animals experienced vaginal opening on average at postnatal day 21 (P21) as expected (Figure 
2.1B, range: P18-P28, n=11), while Npr2pwe/pwe females experienced vaginal opening from P33-
P84 (Figure 2.1B, n=6).  The extensive delay in puberty in individual Npr2pwe/pwe females 
appears to correlate with their body weight (Appendix 2.1).  Body weight is a known predictor of 
the onset of puberty in mice (32, 33) and humans (34).  
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 To determine whether post-pubertal Npr2pwe/pwe females were capable of cycling through 
estrus, vaginal smears were taken for 20 consecutive days and estrous stage was assigned by 
vaginal cytology (31).  Control (n=7) and Npr2pwe/pwe (n=4) females cycled normally through all 
stages of the estrous cycle during this 20-day period (Figure 2.4A).  The amount of time spent in 
each of stage of the cycle did not differ between mutants and controls (Figure 2.4A).  Thus, 
while Npr2pwe/pwe females have a delay in the onset of puberty, they are capable of cycling 
through estrus normally, suggesting that the hypothalamus and pituitary are functioning properly 
to regulate the estrous cycle (31, 35).  The diestrus uterine histology of Npr2pwe/pwe females is 
normal at 12 weeks of age, indicating that the uterine tissues, including the endometrium, 
myometrium, and stromal glands, are intact (Figure 2.4C).  
 To assess ovarian follicle development in the Npr2pwe/pwe female, we stimulated pre-
pubertal females with PMSG, which stimulates follicle growth to the pre-ovulatory stage.  
Oocytes are arrested around birth at prophase I, and this is morphologically distinguished by the 
presence of a germinal vesicle (13, 15, 36-38).  The germinal vesicle is normally maintained 
until the pre-ovulatory follicle receives the surge of LH that promotes meiotic resumption and 
ovulation (13, 15, 36-38).  At this point, the germinal vesicle will break down, the meiotic 
spindle is formed, and the first meiotic division is completed with the extrusion of the first polar 
body (13, 15, 36-38).  Pre-ovulatory follicles in the ovaries of PMSG-primed control females 
contained oocytes (either released from ovarian follicles or in sections of whole ovaries) with 
intact germinal vesicles (Figure 2.5A).  However, Npr2pwe/pwe oocytes had progressed 
prematurely through meiosis; virtually all oocytes examined underwent premature germinal 
vesicle breakdown (GVBD) (Figure 2.5A).  Some had formed meiotic spindles, or extruded one 
or even two polar bodies (Figure 2.5A).  Cyclic GMP (cGMP), which is generated by NPR2, is  
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Figure 2.4. Npr2pwe/pwe females cycle through estrus, have normal levels of estradiol and 
FSH, form corpora lutea, and have normal uterine histology.  Panel A: Estrous cycles of two 
representative Npr2pwe/pwe females (black symbols and lines) and controls (white symbols and 
grey lines) over a 20-day consecutive period show all stages of the estrous cycle (P=proestrus, 
E=estrus, M=metestrus, and D=diestrus, top panel).  Npr2pwe/pwe females spend similar amounts 
of time in each stage of the estrous cycle as controls.  Panel B: 8 week Npr2pwe/pwe ovaries 
contain corpora lutea at metestrus (arrowheads).  Panel C: 12 week Npr2pwe/pwe uterine histology 
at diestrus is normal, including the presence of stromal glands (arrows). 

















Figure 2.5.  Npr2pwe/pwe female infertility is caused by a failure in meiotic arrest, leading to 
the release of oocytes that are not viable.  Panel A: Oocytes from unaffected (+/-) and 
Npr2pwe/pwe mice were released from pre-pubertal PMSG-primed antral follicles by needle 
puncture and examined by light microscopy with DIC optics (left).  Almost all unaffected 
oocytes had a single pronucleus while most oocytes from Npr2pwe/pwe follicles exhibited GVBD 
(Germinal Vesicle Breakdown) and premature formation of polar bodies.  The percentage of 
oocytes that underwent GVBD is shown at the far right (top).  Data are the mean ± SEM of three 
separate experiments.  Histological sections from fixed ovary tissues from the same mice (center 
panels) revealed premature meiotic spindle formation in mutants.  Extracts from pre-pubertal 
PMSG-primed antral follicles had measurable levels of cGMP in controls, but undetectable 
levels in mutants (far right, bottom).  Data are the mean ± SEM of three separate experiments.  
Panel B: Superovulated pre-pubertal wild type (+/+) mice released normal eggs whereas nearly 
all mutant oocytes underwent fragmentation.  When wild-type and Npr2pwe/pwe females were 
superovulated and mated with wild-type males, Npr2pwe/pwe females (black bars) released fewer 
oocytes compared with the wild type (white bars).  Most of the mutant oocytes were not 
fertilized and mutant zygotes failed to develop to 2-cell embryos.  Data are the mean ± SEM 
(Control, n=6; Mutant, n=4) 
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known to inhibit progression through meiosis (39, 40).  The level of cGMP in Npr2pwe/pwe antral 
follicles was reduced to undetectable levels (Figure 2.5A).   Thus, Npr2 is essential for cGMP 
production and maintenance of meiotic arrest in the oocyte. 
 To determine whether Npr2pwe/pwe females were capable of releasing fertilizable oocytes 
into the oviducts, we superovulated pre-pubertal Npr2pwe/pwe females as described in the Methods 
and mated them with a proven wild-type male.  Npr2pwe/pwe females ovulated fewer oocytes than 
controls (Figure 2.5B), and they underwent oocyte fragmentation, a precursor to oocyte cell 
death (41).  None of the Npr2pwe/pwe oocytes progressed to the two-cell embryo stage.  
We tested the natural ability of Npr2pwe/pwe females to ovulate by conducting natural 
mating experiments with mature, post-pubertal animals.  Npr2pwe/pwe females released similar 
numbers of oocytes when compared to controls (Npr2pwe/pwe, n=6 and control, n=6), data not 
shown).  We measured levels of FSH and estradiol.  Levels of both hormones at diestrus were 
normal (Table 2.2).  Levels of LH and FSH from individual male and female pituitaries 
determined by RIA were also normal (data not shown).  Sections through Npr2pwe/pwe ovaries at 8 
and 12 weeks revealed the presence of corpora lutea (Figure 2.4B), consistent with ovulation (35, 
42).  Together, these data indicate that the hypothalamus and pituitary of Npr2pwe/pwe females are 
functioning well enough to support ovulation and the ovary responds with appropriate steroid 
hormone production (35, 42).  
Table 2.2. Normal Hormone Levels In peewee Females 







*Multiplex testing on serum samples collected at diestrus (Control, n=8; peewee, n=8) 
**ELISA on serum samples collected at diestrus (Control, n=8; peewee, n=8) 
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Npr2 and Bone Tissue Mineral Density 
 Npr2 is expressed in osteoblasts as well as chondrocytes (43), and data suggest that CNP-
NPR2 signaling may augment osteoblast differentiation in combination with other factors (44).  
It is hypothesized that many disruptions in the growth plate also affect the normal function of 
osteoblasts or osteoclasts (7).  We assessed whether bone was defective in mineralization or 
integrity by microscopic computed tomography (microCT) scans of 12-week old male femurs 
and L4 vertebrae (Control, n=6; mutant, n=7).  No major deficits in the mineralization of 
trabecular and cortical bone of Npr2pwe/pwe males were observed (Appendix 2.1).  Therefore, 
while Npr2 is expressed in osteoblasts, the loss of Npr2 in this cell type does not appear to affect 
proper mineralization of long bones and vertebral elements. 
Elevated levels of phosphorylated ERK1/2 in Npr2pwe/pwe tibiae 
The fibroblast growth factor (FGF) signaling axis is a potent activator of the MEK/ERK 
MAPK pathway in the growth plate (45, 46) (Figure 2.6A).  Gain-of-function mutations in the 
gene that encodes FGF receptor 3 (FGFR3) cause achondroplasia in humans (1, 6, 7, 46, 47).  In 
cultured chondrocytes, activation of MEK/ERK leads to a reduction in the production of 
extracellular matrix proteins, differentiation, and possibly proliferation (45, 46).  The cGMP 
generated by NPR2 upon binding CNP activates cGMP-dependent protein kinase II (PKGII), 
which goes on to inhibit the activation of RAF-1, the activator of MEK1/2 (45).  Thus, NPR2 
signaling halts the MEK/ERK MAPK cascade at the level of RAF-1 (Figure 2.6A) through its 
activation of PKGII (45) in vitro.  
We hypothesized that if Npr2pwe/pwe mice lack the critical receptor required for 
MEK/ERK inhibition, they should have increased levels of phosphorylated ERK1/2.  Western 
blot analysis was performed using postnatal day three (P3) tibial lysates.  Higher levels of 
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phosphorylated ERK1/2 were observed in lysates prepared from mutant tibiae relative to wild 
type (Figure 2.6B).  Thus, signaling through NPR2 inhibits the activation of the MEK/ERK 
MAPK pathway in intact bone. 
Therapy for the Npr2pwe/pwe growth defect  
We reasoned that treatment of Npr2pwe/pwe mice with a pharmacological inhibitor of the 
MEK/ERK MAPK pathway might improve bone growth.  We cultured fetal tibiae harvested at 
embryonic day 16.5 for six days as explants in the presence of vehicle (DMSO) or the MEK1/2 
inhibitors U0126 and PD325901 (Figure 2.7A) (26, 48-52).  PD325901 is a potent MEK1/2 
inhibitor (52), and has been used to study mouse cancers (48, 49).  After the culture period, the 
tibiae were photographed and measured (Figure 2.7).  Mutant tibiae were shorter than wild type 
after treatment with vehicle, and both inhibitors induced growth of wild type and mutant tibiae.  
PD235901 induced more growth than U0126.  Two-way ANOVA and Bonferroni post-hoc 
analysis confirmed that the effects of both treatments were highly significant (Figure 2.7B, 
p<0.0001, n=16 of both genotypes for U0126, n=7 of both genotypes for PD325901).  Drug-
induced growth of the normal tibiae suggests that CNP signaling is rate limiting in normal mice.  
Western blots revealed reduced phosphorylated ERK1/2 in U0126-treated animals, 
demonstrating that the drug effectively inhibited MEK/ERK activation in explants from normal 
and mutant mice (Figure 2.7C). 
The histology of sections from cultured tibiae suggested that the primary effect of U0126 
on wild type and mutant tibiae was to expand the size of the hypertrophic zone (Figure 2.7A).  In 
situ hybridization was performed to assess expression of Col10a1 (53) (collagen 10, alpha 
subunit), a marker of hypertrophic chondrocytes (Figure 2.7A).  The cells in this expanded zone  
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Figure 2.6. FGF and CNP signaling pathways converge at the MEK/ERK pathway and 
Npr2pwe/pwe mutants have elevated phosphorylated ERK1/2.  Panel A: Diagram detailing the 
key components involved in the FGF and CNP pathways in the growth plate, and the outcomes 
of activation of these pathways (7, 45, 46, 51, 54, 55).  Panel B: Western blots on postnatal day 3 
individual tibial lysates (1 tibia per lane) indicate that Npr2pwe/pwe tibiae (-/-) have elevated levels 
of phosphorylated ERK1/2 (p-ERK1/2) relative to wild type (+/+) but similar levels of total 
ERK1/2.  Blot images are representative exposures of membranes incubated first with p-ERK1/2 




















Figure 2.7. MEK1/2 inhibitors rescue the Npr2pwe/pwe growth defect in explants.  Panel A: 
Treatment with the inhibitor U0126 increases the length of mutant and wild type tibiae by 
increasing the hypertrophic zone.  Both wild type and mutant whole tibiae are obviously longer 
than their DMSO (vehicle) treated contralateral controls.  Sections stained with nuclear fast red 
and alcian blue show the expansion of the hypertrophic zone (vertical arrows) upon treatment.  In 
situ hybridization reveals Col10a1 transcripts in the hypertrophic zone of all samples.  Panel B: 
Quantification of tibial length in U0126 (n=16 for both genotypes) and PD325901 (901) (n=7 for 
both genotypes) treated mutants (-/-) relative to wild type (+/+).  Treatment of both genotypes 
with either inhibitor leads to a highly significant increase in length (p<0.0001).  The PD325901-
treated cohort is significantly longer than those treated with U0126 (p<0.01).  Letters indicate 
groups that are significantly different from one another (a,b,c), while the superscript numbers 
indicate the two different treatment groups (1: U0126, 2: PD325901)  Panel C: Western blot of 
phosphorylated ERK1/2 conducted on U0126-treated tibiae of both genotypes harvested at E16.5 
and cultured in the presence of vehicle (DMSO) or U0126 for 6 days indicates that U0126 
inhibits activation of ERK1/2 without altering levels of total ERK1/2 protein.  Each lane contains 
lysates pooled from 4 individual tibiae of each genotype and treatment.  Blot images are 
representative exposures of membranes incubated first with p-ERK1/2 primary antibody, 
stripped, and incubated with total ERK1/2 primary antibody. 
 
 




of the growth plate are marked with Col10a1 transcripts, confirming that these are hypertrophic 
chondrocytes. 
Discussion  
We have identified the genetic defect in peewee, a new spontaneous mutant allele of 
Npr2, with growth insufficiency and female infertility.  The phenotype is caused by a 4-bp 
deletion in exon 3 of Npr2 that generates a premature stop codon at codon 313.  This leads to 
truncation of the receptor within the ligand-binding domain and a predicted null allele due to the 
loss of all domains C-terminal to the mutation.  Other null alleles of Npr2 with similar skeletal 
and growth insufficiencies have been reported, but previous characterization focused on other 
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aspects of Npr2 function including blood pressure regulation and gastrointestinal tract function 
(25, 26).  Here we report a comprehensive analysis of female infertility and a bone growth in 
response to pharmacotherapy. 
Since Npr2 is expressed in all the major organs of the female reproductive tract (18, 27-
30), we addressed the possibility that multiple organs could contribute to peewee female 
infertility.  We show for the first time that Npr2-deficient females exhibit a delay in puberty, and 
this delay correlates with the body size (32, 33).  Once Npr2pwe/pwe females reach puberty, they 
progress through all stages of the estrous cycle and are capable of ovulating in response to 
exogenous and natural stimulation.  Our results differ from previous reports that the Npr2 knock 
out allele caused loss of cycling, uterine atrophy, reduced endometrial and myometrial layers, 
and absent stromal glands (26).  The differences are likely due to genetic background effects.  
We characterized Npr2pwe/pwe on a mixed background that supports viability, but the mutation has 
reduced viability on other backgrounds, similar to reports for other Npr2 alleles.  Susceptible 
background strains may offer less compensation for Npr2 deficiency in a variety of organs that 
express Npr2, including the uterus and pituitary gland.  Genetic compensation could involve 
variable cross talk between other natriuretic peptide receptors and ligands.   
Npr2pwe/pwe females have normal serum levels of FSH and estradiol at diestrus and 
naturally ovulate, indicating that hypothalamic stimulation of the pituitary by pulsatile GnRH 
secretion and pituitary secretion of FSH and LH (35) are occurring.  This is surprising, given that 
Npr2 is expressed at all points of the female HPG axis (18, 27-30), and natriuretic peptide 
signaling through NPR2 was proposed to play a role in gonadotropin production (29).  
Importantly, this work and the work of others (56) clearly demonstrate that Npr2 signaling is not 
required for HPG axis function in the female in the context of this genetic background. 
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The primary cause of female infertility in Npr2pwe/pwe females is premature oocyte meiotic 
resumption.  We show that in Npr2pwe/pwe mice, impaired cGMP production in ovarian follicles is 
associated with premature oocyte maturation and impaired embryonic development.  Our 
findings support the requirement for NPR2 to maintain the production of cGMP in ovarian 
follicles to ensure oocyte meiotic arrest (27).  Although Npr2pwe/pwe females are able to ovulate in 
response to exogenous or endogenous gonadotropin stimulation, the oocytes undergo 
fragmentation (41).  This has been reported in Npr2cn/cn mutants, mice with reduced levels of 
CNP (Nppclbab/lbab), and in the G-protein coupled receptor 3 mutant mouse (Gpr3-/-)  (56).  Gpr3-/- 
oocytes have reduced levels of cAMP, leading to premature meiotic resumption and oocyte 
fragmentation (41).  Taken together, the primary site of Npr2pwe/pwe female infertility is the 
oocyte.  None of the descriptions of people affected with AMDM discuss female fertility (16, 17, 
20-22).  Our studies suggest that if AMDM female patients are infertile due to a failure to 
maintain oocyte meiotic arrest, they may be able to bear children using donor eggs, provided that 
uterine and placental function are normal. 
Endochondral bone ossification involves the differentiation of condensed mesenchymal 
cells into chondrocytes that will proliferate and undergo terminal hypertrophic differentiation to 
ultimately promote the vascularization, mineralization, and recruitment of osteoclasts and 
osteoblasts into the nascent element (1, 5, 6).  The trabecular and cortical tissue mineral density 
of femurs and L4 vertebral elements are normal in Npr2pwe/pwe mice, even though the receptor is 
expressed in osteoblasts (43).  It is clear that the main role of the CNP-NPR2 signaling axis in 
skeletal elements is to regulate their longitudinal growth through action in the growth plate.  
Without Npr2, chondrocyte hypertrophy is compromised, so the bones of mutant animals will 
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never reach a normal adult length, although the bone tissue laid down is normal in its 
composition. 
Both the proliferative and hypertrophic zones of the growth plates in Npr2pwe/pwe animals 
appear reduced in size, consistent with the Npr2 knock-out mouse (26) and other spontaneous 
mutant alleles of Npr2 (23, 24).  Loss of Npr2 does not affect the overall organization of the 
growth plate, but probably affects either the overall number of chondrocytes recruited to undergo 
hypertrophic differentiation, the rate in which they commit to this fate, and/or the rate in which 
they proliferate.  We observed elevated activation of ERK1/2 in whole mutant tibial lysates, 
which demonstrates that NPR2 is required for ERK1/2 inhibition in vivo, as predicted by in vitro 
cell culture studies (45).  
Treatment for skeletal dysplasia involves multiple lengthening surgeries for the long 
bones (1, 47).  These surgeries are expensive, time consuming, fraught with many possible 
complications, and ultimately result in only a modest increase in bone length (1, 47).  In general, 
the acceptance of short stature is advocated in the USA by patients, their families, and advocacy 
groups for individuals with severe short stature (1).  There are currently no effective 
pharmacological therapies for individuals with skeletal dysplasia (1).  Growth hormone treatment 
has been attempted in achondroplasia patients without much success (1, 47).  C-Type Natriuretic 
peptide (CNP), the ligand of NPR2, is a very promising new therapeutic candidate that has been 
shown to rescue growth defects in mouse models of achondroplasia both genetically and 
pharmacologically (7, 51, 54, 57).   While this therapeutic approach could offer hope for 
achondroplasia patients and their families, this form of therapy would be ineffective in AMDM 
patients that lack the receptor for CNP (16).   
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There are no reports of growth promoting pharmacotherapy for Npr2 mutants.  Here we 
report successful elongation of Npr2pwe/pwe mutant tibiae and inhibition of MEK/ERK MAPK 
signaling within these tibial explants through utilization of the MEK1/2 inhibitors U0126 and 
PD325901.  We also show that MEK1/2 inhibitor treatment extends the length of the 
hypertrophic zone, consistent with the proposed role of ERK1/2 inhibition in the promotion of 
hypertrophic differentiation (7, 45, 51, 58).  PD325901 treatment led to a more dramatic increase 
in tibial length compared to U0126.  This could be due to the fact that PD325901 is known to be 
a more potent MEK1/2 inhibitor, and has been successfully administered to the whole animal in 
cancer studies (42, 49).  PD325901 has also been administered orally in clinical trials (52, 59).  
Thus PD325901 as well as other structurally related agents that are currently undergoing clinical 
evaluation in cancer are promising therapeutic candidates for growth defects associated with 
excess MEK1/2 signaling, including patients with AMDM, achondroplasia or other appropriate 
skeletal dysplasias.  We have administered U0126 to Npr2pwe/pwe mice, as another group had done 
with a mouse model of Apert Syndrome (50), but the results were difficult to reproduce in 
Npr2pwe/pwe animals (data not shown).  We leave this avenue of future study open to experts in 
pharmacotherapy.  The key to moving skeletal dysplasia therapeutics forward will be to deliver 
this class of agents specifically to the growth plate, and individuals with expertise in the realm of 
pharmacology will be better suited to address this issue.  
We have identified a novel null allele of Npr2 and characterized the effect on long bone 
growth and female fertility.  In addition, we have established a proof of principle for 
pharmacotherapy to correct poor bone growth.  The next challenge is to develop efficacious 
delivery methods and treatment regimes in intact animals, minimizing effects on other tissues.   
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Materials and Methods 
Generation of peewee mice and mapping of the mutation.  The peewee mutation arose 
spontaneously on the NAW/WI strain in Glen Wolfe’s laboratory at the University of Kansas 
(Lawrence, Kansas).  The mice were then transferred to Andrzej Bartke’s laboratory at Southern 
Illinois University (SIU, Carbondale, Illinois).  The line was maintained at SIU by outcrossing 
for hybrid vigor.  Upon transfer to the University of Michigan in vitro fertilization was carried 
out with oocytes from C57BL/6J females (The Jackson Laboratory, Bar Harbor, Maine) and 
sperm from a single homozygous peewee male from a mixed background including contributions 
from the NAW/WI, C57BL/6, and C3H/HeJ strains.  The fertilized eggs were transferred to 
surrogate mothers yielding pwe heterozygotes that were a mixture of all these backgrounds.  
Heterozygotes were bred to (C57BL/6J X C3H/HeJ) F1 mice (The Jackson Laboratory, Bar 
Harbor, Maine), and the heterozygous progeny of this cross were intercrossed to generate mutant 
animals for analysis.  These pwe heterozygotes were also crossed to Mus castaneus and F1 
progeny were intercrossed to map the mutation by genotyping SNPs (19) and microsatellite 
markers.   
 All mice were housed in a specific pathogen free facility with 12-h light, 12-h dark cycle in 
ventilated cages with unlimited access to tap water and Purina 5020 chow.  All procedures using 
mice were approved by the University of Michigan Committee on Use and Care of Animals 
(UCUCA), and all experiments were conducted in accordance with the principles and procedures 
outlined in the National Institutes of Health Guidelines of the Care and Use of Experimental 
Animals.  
Skeletal preparation and histology.  Skeletal preparations of whole, skinned adult mice were 
prepared by fixation in 95% ethanol overnight, stained with Alcian Blue, treated with 2% KOH, 
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stained with Alizarin Red, and stored in glycerol.  Bones from affected and unaffected animals 
were measured with calipers for determination of disproportionate dwarfism.  Five week old 
male tibiae were fixed overnight in 4% formaldehyde in PBS, decalcified as described previously 
(60), dehydrated through an ethanol series, and embedded in paraffin.  Tibiae were sectioned and 
stained with hemotoxylin and eosin. 
Analysis of the onset of puberty and estrous cyclicity.  Females were observed for date of 
vaginal opening daily from P18-P28, and estrous cycles were monitored by vaginal cytology 
every day for a 20-day period between 8 and 12 weeks of age as described (31).  
Hormone measurements. Females were sacrificed at 12 weeks of age at diestrus.  Serum was 
prepared from blood samples after clotting for 90 minutes at room temperature, running a 
wooden toothpick along the sides of the collection tube, and spinning the samples at 2,000Xg for 
15 min.  The serum supernatant was removed and stored at -20°C until analysis.  Analysis was 
performed by the University of Virginia Ligand Core. 
Analysis of oocytes, ovaries, and uterus.  Prepubertal female mice were stimulated with 5 IU 
pregnant mare’s serum gonadotropin (PMSG) to stimulate follicle growth to the preovulatory 
follicle stage and euthanized 46 hours later (61).  Oocytes were released from antral follicles 
from one ovary by needle puncture.  The other ovary was fixed overnight in Bouin’s fixative 
(Ricca Chemicals), dehydrated in an ethanol series, followed by n-butanol, and embedded in 
paraffin.  Sections were stained with Mayer’s hemotoxylin and eosin.  Uteri were dissected from 
12-week old females at diestrus, fixed for 1 hour in 4% PFA, dehydrated through an ethanol 
series and embedded in paraffin.  Sections were stained with hemotoxylin and eosin. 
cGMP Quantification.  Intact antral follicles were dissected from PMSG-primed ovaries of 
mutant and control females as previously described (62).  The follicles were processed for cGMP 
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quantification according to the manufacturer’s instructions (Cyclic GMP EIA Assay, Cayman 
Chemical # 581021). 
Superovulation. Prepubertal females were stimulated with 5 IU PMSG followed 46 hours later 
by 5 IU human chorionic gonadotropin (hCG) to induce the superovulation of oocytes (61) and 
placed with an experienced wild-type male overnight.  The morning after hCG administration, 
females were observed for a copulation plug, and fertilized eggs were collected, counted and 
cultured in M16 media at 37°C in 5% CO2 for 4 days to observe normal early embryonic 
development (61). 
Natural mating experiments.  12 week old mutant and control females were placed with an 
experienced hybrid male (C57BL/6J X C3H/HeJ F1, The Jackson Laboratory, Bar Harbor, 
Maine) for a week and observed daily for evidence of a copulation plug.  The day of the plug, 
females were euthanized and their oviducts were flushed with a blunted needle filled with a 6% 
BSA/1 X PBS solution.  Oocytes were counted under a dissection microscope. 
Micro-computed tomography.  Specimens were dissected free of soft tissue and analyzed by 
micro-computed tomography (µCT, eXplore Locus SP, GE Healthcare Pre-Clinical Imaging, 
London, ON, Canada).  Specimens were immersed in water and scanned 4 (femora) or 12 
(vertebrae) at a time using the Parker method (180 degrees plus a 20 degree fan angle) of rotation 
at 80 kVp and 80µA and added filtration in the form of both an acrylic beam flattener and a 0.02 
inch aluminum filter.  Images were reconstructed at an isotropic voxel size of 18µm and 
calibrated for densitometry. A region of interest 20 and 25 percent of the mid-diaphysis was 
isolated from the femora for trabecular and cortical analysis, respectively. A region of interest 
including centrum of the vertebrae and excluding the spinal processes was segmented out for 
trabecular analysis. Manufacturer software (MicroView v2.2, GE Healthcare Pre-Clinical 
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Imaging, London, ON, Canada) was used to calculate trabecular bone volume fraction (BV/TV), 
bone surface-to-volume ratio (BS/BV), thickness (Tb.Th), number (N), and spacing (Tb.Sp) 
along with bone mineral content (BMC), tissue mineral density (TMD), and periosteal and 
endosteal perimeters after applying a uniform threshold of 1200 Hounsfield Units (HU) for 
trabecular analyses and 2000 HU for cortical analyses. 
Tibial cultures and analysis.  Tibial cultures were performed as previously described (26).  
U0126 was purchased from Promega (#V1121), and PD325901 was purchased from LC 
Laboratories (#P-9688).  Both of these inhibitors were used at a final concentration of 10 µM.  
On the sixth day of culture, tibiae were photographed under a 2.5X objective lens under a 
dissection microscope and used for histological analysis or frozen at -80°C for protein analysis.  
Enlarged photographs were printed and measured with a ruler in centimeters to determine their 
lengths in arbitrary units.  For histological analysis, cultured tibiae were fixed overnight in 4% 
formaldehyde in PBS, dehydrated through and ethanol series, and embedded in paraffin.  Nuclear 
Fast Red/Alcian Blue staining was performed as previously described (63).  In situ 
hybridizations were performed as previously described (64).  The Col10a1 probe (53) was a 
generous gift from Ernestina Schipani (Indiana University). 
Western blotting.  Total protein from cultured tibiae and P3 tibiae was extracted in T-PER® 
buffer (Thermo/Pierce #78510) and Halt™ Protease and Phosphatase Inhibitor Cocktail 
(Thermo/Pierce #78440).  Total protein was quantified using a BCA Protein Assay Kit 
(Thermo/Pierce #23225).  Proteins and ladder (BIO-RAD #161-0375) were run on 4-20% Mini-
Protean® TGX™ Gels from BIO-RAD (#456-1093S (10 well)) and transferred to an Amersham 
Hybond™-P membrane (GE Healthcare).  Membranes were washed with a standard Tris-
buffered saline solution with Tween-20 (TBS-Tween).  ERK antibodies were purchased from 
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Cell Signaling Technology (phospho-ERK1/2: #4370, total ERK1/2: #4695) and diluted as per 
the manufacturer’s instructions.  Anti-beta actin was obtained from Abcam and used at a 1:2500 
dilution.  Goat-anti-rabbit conjugated to horseradish peroxidase (HRP) secondary antibody was 
purchased from Thermo Scientific (#31462) and was diluted 1:25,000.  Membranes were 
blocked and incubated with antibody in a 1% BSA/TBS-Tween solution.  BSA was purchased 
from Cell Signaling Technology (#9998S).  Membranes were developed with the SuperSignal® 
West Pico Chemiluminescent Substrate (Thermo/Pierce #34080) and stripped with Restore™ 
Western Blot Stripping Buffer (Thermo/Pierce #21059).       
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APPENDIX 2.1 
 
Appendix 2.1.  Npr2pwe/pwe female pubertal delay coincides with lower body weight, and 
Npr2pwe/pwe bones exhibit normal tissue mineral density.  Panel A: Growth curve of a 
representative litter of Npr2pwe/pwe females (n=3 shown individually) with dates of vaginal 
opening indicated with arrowheads.  Control females (n=6) are graphed as an average and 
average vaginal opening is indicated with an arrow.  Panel B: Trabecular tissue mineral densities 
of Npr2pwe/pwe male L4 vertebrae and femurs are normal, as is the cortical tissue mineral density 
of the femur in the same males (Control, n=6; Npr2pwe/pwe, n=7)
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CHAPTER 3 
chagun, a Hypomorphic Allele of Poc1a, Models Primordial Dwarfism 
 
Abstract 
Skeletal dysplasias are a common, genetically heterogeneous cause of severe short 
stature.  Disruptions in many pathways can cause skeletal dysplasia, including signal 
transduction, extracellular matrix components, control of protein trafficking and glycosylation, 
and control of gene expression at the levels of transcription, RNA processing and translation.  An 
emerging new group includes genes involved in the development and function of centromeres 
and cilia.  Using exome and genomic sequencing we identified a hypomorphic mutation in the 
mouse Poc1a gene, which encodes a protein of the centriole and cilia.  Affected mice have 
skeletal dysplasia, severe growth insufficiency, and male infertility. While Poc1a is broadly 
expressed, strong expression is evident in sperm and the proliferative zone of the growth plate.  
We show that growth insufficiency results from cellular disorganization at the growth plate.  
Infertility is due to progressive germ cell loss and reciprocal spermatagonial stem cell transplants 
indicate Sertoli cell dysfunction.  Genome variation influences the viability of the mutant mice, 
and humans with hypomorphic POC1A mutations have severe short stature and variable 
associated features.  This mouse model will be invaluable for identifying the genes that modify 
the clinical features, understanding the pathophysiology of ciliopathies that cause growth 
insufficiency and developing therapeutics.
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Introduction 
 
Normal adult stature in humans is achieved primarily through regulation of long bone 
growth, which occurs through a process known as endochondral ossification (1, 2).  This process 
begins early in embryonic development and results in the differentiation of mesenchymal cells 
into chondrocytes throughout the body where skeletal elements will eventually reside.  
Hypertrophic differentiation of these chondrocytes directs the vascularization of the forming 
element, allowing osteoblasts to enter and mineralize the cartilage-based template.   
Pools of cells at the epiphyses of the long bones retain their cartilage identity as a means 
to secure the progressive addition of bone matrix throughout the period of skeletal growth (1).  
These structures are the epiphyseal growth plates.  Tight control of chondrocyte proliferation and 
terminal hypertrophic differentiation, allows new bone tissue to be laid down in the place of 
dying chondrocytes in a spatially and temporally regulated manner, ensuring the proper growth 
of the skeletal elements and the individual overall (2). 
The growth plate maintains a highly ordered architecture to carry out its function and it is 
divided into several distinct zones (1, 2).  In the resting zone, lesser-differentiated chondrocytes 
await further direction to undergo rounds of cell division and enter the proliferative zone of the 
growth plate.  These cells are guided to undergo terminal hypertrophic differentiation in the 
hypertrophic zone of the growth plate.  Perturbation of growth plate organization can result in 
profound growth defects in mice and humans (3-5).  Major orchestrators of growth plate 
architecture include the WNT-planar cell polarity pathway (6), the TGFβ/BMP signaling 
pathways (4), and the primary cilium (3).   
These disorganization phenotypes are particularly evident in the proliferative zone of the 
growth plate, where a process known as chondrocyte rotation occurs (3, 6, 7).  The proliferative 
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zone forms distinctive columns of disc-shaped chondrocytes that resemble stacks of coins.  
These columns form through the directed cell division of chondrocytes perpendicular to the 
plane of the growth plate, followed by sliding of the newly formed daughter cells over one 
another.  It is not known what advantage this process grants the growth plate, but disruption of 
chondrocyte rotation results in impaired longitudinal growth of the long bones (3). 
Primordial dwarfisms are a subset of growth insufficiency disorders caused by defects 
intrinsic to the skeleton that are classified as forms of skeletal dysplasia (8, 9).  Rather than 
exhibiting a disproportionate reduction of long bone length, where elements are affected 
differentially, primordial dwarfism causes a proportionate reduction in longitudinal growth that 
commences early in fetal life (8).  The proportionate reduction in growth and onset of the growth 
defect in these patients highly resembles insulin-like growth factor type 1 (IGF-1) deficiency.  
Primordial dwarfisms result in profound reductions in height, with some patients only reaching 
an adult height of 1 meter.     
The primordial dwarfisms include Seckel Syndrome, Microcephalic Osteodysplastic 
Primordial Dwarfism I-III (MOPD I-III), and Meier-Gorlin Syndrome (MGS) (8).  The genetic 
causes of the primordial dwarfisms do not appear to cause endocrine disturbances, but rather 
interfere with processes that are intimately connected to the cell cycle (8).  Common pathways 
that are disrupted in primordial dwarfism patients include: DNA repair (10-13), DNA replication 
(14-17), centrosome-mediated processes (13-16, 18-23), and splicing of specific subsets of 
introns in mRNA transcripts (24, 25).   
A novel form of microcephalic primordial dwarfism in humans, was recently shown to be 
caused by mutations in the gene that encodes protein of centriole 1A (POC1A) (22, 23).  Human 
patients exhibit intrauterine growth retardation, severe short stature throughout their lives, and a 
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distinctive, triangular-shaped face.  Variable incidences of developmental delay, failure to thrive, 
sparse hair, and delayed bone age have been reported.  Patients homozygous for a nonsense 
mutation (R81X) exhibit read-through translation that results in expression of 50-85% of the 
normal level of POC1A protein in fibroblasts, when it is expected that little to no protein would 
be present (23).  This has led to a hypothesis that mutations in POC1A may actually represent 
hypomorphic alleles as opposed to true null alleles.   
We recently discovered the gene responsible for skeletal dysplasia and male infertility in 
the chagun mouse, a previously described, spontaneous, recessive mouse mutation (26).  The 
mutation is a hypomorphic allele of Poc1a that produces normal levels of POC1A protein that 
lacks 23 amino acids.  This domain is clearly necessary for normal growth plate architecture.   
We also show that the infertility of male Poc1acha/cha mice is due to progressive loss of germ 
cells, which is likely caused by Sertoli cell dysfunction.  Thus, this animal model has clarified 
the molecular basis for the clinical features in human patients with POC1A mutations.   
Results  
chagun is caused by a mutation in Poc1a 
The chagun mutation arose on DBA/2J and was mapped to Chr 9 in 129 progeny of an 
F1 x F1 intercross with CAST/Ei to a 6 cM region of mouse Chr 9 (26).  We arranged for 
genome wide exome capture and high throughput sequencing of a chagun genomic DNA sample 
(Mutant Mouse Resequencing Project, The Broad Institute of MIT and Harvard, Cambridge, 
MA).  At least 2X coverage was obtained from the exons in the critical interval.  No nonsense 
mutations or disruptions in consensus splice sites were uncovered in the critical interval using 
this approach.  There were some synonymous changes and a single missense mutation that 
encoded an amino acid normally present in other species.  Some variants were detected in 
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intronic regions captured with the exons, but none appeared likely to disrupt splicing or create 
ectopic splice donors or acceptors (Appendix 3.1).    
Having found no obvious deleterious mutations with exome sequencing, we turned to 
regional DNA capture to enrich for non-repetitive genomic DNA in the most broadly defined 8.5 
Mb chagun critical region (D9Mit183-D9Mit212).  We captured genomic DNA from an obligate 
carrier (cha/+) and a known mutant (cha/cha).  We obtained high throughput sequence with at 
least 20X coverage for approximately 90% of the bases sequenced from both samples.  We 
detected five new insertions of transposable elements that are not present in the 16 mouse 
reference genomes (Appendix 3.2).  
We observed a steep decrease in coverage in the middle of exon 8 of the gene that 
encodes protein of centriole 1A (Poc1a) (Figure 3.1A).  Reduced coverage is more obvious in 
the mutant than the heterozygote.  In addition, many sequencing reads that map to exon 8 in the 
mutant have paired ends that map to other locations in the genome: chromosomes 5, 10, and 12, 
rather than chromosome 9.  Together, these data suggest that an element repeated on three 
chromosomes is inserted in Poc1a exon 8.  PCR amplification of exon 8 and flanking intronic 
regions using chagun genomic DNA as the template amplified a product 500 bp larger than the 
product generated from unaffected animals (Figure 3.1B).  Sanger sequencing of the genomic 
amplification products indicated that exon 8 is disrupted by the insertion of a partial transcript of 
centromere protein W (Cenpw) that has approximately 30 nucleotides of poly-A.  Cenpw is 
located on mouse chromosome 10, and there are two locations in the mouse genome that also 
contain complementary sequence on chromosomes 5 and 12, which are most likely pseudogenes, 
due to the fact that they are also complementary to the Cenpw mRNA transcript.  The insertion  
 














Figure 3.1. The chagun phenotype is caused by a LINE-1 mediated insertion of a processed 
transcript into exon 8 of Poc1a. Panel A. Screenshots from the Broad Institute’s Integrative 
Genomics Viewer (IGV) show a drop in paired end sequence coverage within exon 8 of Poc1a. 
Pink reads indicate that the other end of the mate pair maps a different region of the genome. The 
location of exon 8 is indicated by the red rectangles under the sequence reads.  (CVG: coverage) 
Panel B. PCR amplification of genomic DNA with primers designed to intronic regions 5’ and 3’ 
of exon 8 generates an approximately 1100 bp product from the chagun genomic DNA samples 
(right) and the predicted product 613 bp in wild-type genomic DNA (left). NT: No template. 
Panel C. RT-PCR amplification of Poc1a exons 5-10 produces a 526 bp product in cDNA from 
wild-type testis and bone, but the chagun Poc1a transcript is only ~450 bp.  (NT: No template, 
G: Genomic DNA, +/-RT: +/- Reverse Transcriptase).  Panel D.  Sequence of exon 8 in wild 
type and chagun animals.  The cleavage site targeted by LINE-1 is indicated as an arrowhead in 
the wild type and chagun sequences.  The target site and its duplication are underlined. Panel E. 
Schematic diagram illustrating the disruption of chagun genomic DNA by an insertion of a 
transcript complementary to Cenpw (centromere protein W) complete with a poly-A tail.  
Skipping of exon 8 is diagrammed.  The skipping of exon 8 would lead to the deletion of 23 
amino acids in the WD repeat domain (loss delineated by the X and gray shading, LCD: Low 
complexity domain, CCD: Coiled-coil domain, TSD: Target site duplication).  *Indicates 500 bp 
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of the Cenpw processed transcript is unique to the chagun mutants—it is not present in any of the 
16 additional strains analyzed (data not shown). 
All of exon 8 is present, and the insertion point of the processed transcript is flanked by 
short (15 bp) stretches of identical Poc1a sequence, consistent with target-site duplications 
characteristic of a LINE-1 mediated event. Furthermore, there is a LINE-1 retrotransposon ORF-
2 excision site (arrowheads, Figure 3.1D) present in exon 8 that occurs just before the insertion 
of the transcript. These observations have led us to conclude that this is a LINE-1 
retrotransposon-mediated insertion of a mature mRNA transcript of Cenpw.  
The chagun phenotype is caused by a hypomorphic allele of Poc1a   
Tibia RNA was prepared for RT-PCR analysis of Poc1a transcripts.   The chagun cDNA 
produced a smaller amplification product than that detected in normal tibia (Figure 3.1C).  
Sanger sequencing of the mutant RT-PCR product revealed that exon 8 of Poc1a is skipped 
precisely (Figure 3.1E).  Additional RT-PCR analyses did not detect any splicing into exon 8 in 
chagun mutants (Figure 3.2A).  Quantitative RT-PCR was carried out using probes designed to 
amplify exon 2-3 at the 5’ end of the Poc1a transcript and exon 11-12 at the 3’ end of the 
transcript.  The same level of transcripts were detected in wild type and chagun mutants using 
probes for both the 5’ or 3’ ends of the transcript.  This suggests that exon 8 is cleanly skipped 
and that the mutant transcript is equal in stability to the wild type (Figure 3.2B). Skipping exon 8 
preserves the reading frame, and these mutant transcripts are predicted to produce a POC1A 
protein that lacks 23 amino acids in the WD40 repeat domain (Figure 3.1E). 
 Western blots were carried out to assess the level of POC1A protein in tibia.  The 
polyclonal antibody was generated against full-length human POC1A, which is highly conserved  
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Figure 3.2. chagun is likely a hypomorphic allele of Poc1a.  Panel A. RT-PCR amplification 
using primers to detect splicing of exon 7 into exon 8 yields no amplification product from 
cDNA generated from Poc1acha/cha P3 tibiae.  Panel B. Real-Time PCR amplification to detect 
splicing from exon 2-3 at the 5’ end of the transcript and splicing from exon 10-11 at the 3’ end 
of the transcript reveals no significant change in transcript level after the skipping of exon 8 in 
Poc1acha/cha P3 tibiae cDNA samples compared to wild type (WT).  Panel C. Western blots with 
primary antibodies raised against POC1A and Tubulin were conducted on lysates from wild type 
(+/+), heterozygotes (+/-) and Poc1acha/cha (-/-) P3 tibiae run on a 12% SDS-PAGE gel.  Both 
images are exposures taken from the same blot.  
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between human and mouse. A single band was detected in wild type and mutant tibia, consistent 
with a single POC1A protein product.   The level of POC1A protein was normalized against α-  
tubulin, and the POC1A protein is present in chagun mutant tibia at comparable levels to 
unaffected (heterozygotes and wild-type) animals. 
POC1A is expressed in tibial growth plates and seminiferous tubules 
 If the 23 amino acid deletion in Poc1a is responsible for the chagun phenotype, then 
Poc1a must normally be expressed in the affected tissues, namely the skeleton and the testis.  
Immunohistochemistry using a primary antibody against POC1A on sections through two-week 
(postnatal day 14; P14) tibial growth plates (Figure 3.3) show expression in the proliferative 
zone of the growth plate.  The discoid chondrocytes in this zone have robust staining toward one 
side of the cell, which is also seen with markers of the Golgi apparatus (GM130) in the 
proliferative zone (3).  POC1A is expressed in the seminiferous tubules of the testis, and 
particularly intense staining is evident in the region closest to the lumen of the tubule where 
spermatozoa and spermatids are located (Figure 3.3).  This is consistent with strong POC1A 
expression in the post-pachytene stages of germ cell development.  Spermatogenesis is arrested 
at the pachytene stage in chagun mutants (26).  POC1A staining is punctate in the region farthest 
from the lumen near the basement membrane.  Spermatogonia and myeloid cells are located near 
and within the basement membrane, respectively, and spermatocytes are in an intermediate 
position.  Sertoli cells nourish the maturation of sperm, and their nuclei are found above the 
basement membrane and spermatogonia at the level of the tight junctions that form the blood 
testis barrier.  Co-localization studies with antibodies for POC1A and a specific testis cell 
markers will be necessary to determine whether POC1A is expressed in Sertoli cells and 
spermatogonia, in addition to the strong expression in later germ cell development.    . 
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Figure 3.3. POC1A is expressed in the growth plate and seminiferous tubules.  
Immunohistochemistry using an anti-POC1A primary antibody demonstrates expression of 
POC1A (green) in wild-type testis at 3 months and in wild-type tibial growth plates at two weeks 
of age (P14). In the growth plate, POC1A is heavily expressed in the proliferative zone, which is 
evident by the discoid shape of the chondrocytes.  The white box in the top panel indicates the 
area represented in the lower image (R: resting zone, P: proliferative zone).  In the testis, 
expression is robust in the inner layers near the lumen of the seminiferous tubule, and punctate 
staining is observed in cells near the basement membrane (lower panel, arrowheads). Both 
images were acquired using a 40X objective lens.   
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The chagun growth defect is due to a loss of growth plate organization 
 The growth plates of vertebrae and long bones of adult chagun mice were examined 
previously, and the disorganization of the vertebral growth plate was obvious (26).   The weight 
bearing nature of the long bones could have contributed to abnormalities reported in the growth 
plate of the long bones.  Using genotyping for Poc1a exon 8 we examined younger mice.  
Histology of 3-week old tibial growth plates reveals severely disorganized growth plates in these 
long bones (Figure 3.4).   
 
Figure 3.4. The chagun long bone growth plates are severely disorganized.  Standard 
hematoxylin and eosin histological staining on paraffin sections through 3-week old tibial growth 
plates demonstrates profound disorganization of the proliferative zone of the growth plate in 
chagun animals.  Both images were acquired using a 40X objective lens. (R: resting zone, P: 
proliferative zone, H: hypertrophic zone)  
 
chagun males exhibit a progressive germ cell loss  
 chagun  males are infertile (26).  No mature sperm were noted in young adult males, and 
there were fewer germ cells.  Older males had more severe germ cell deficiency.  Mutants had to 
be identified phenotypically as growth insufficient and hypogonadal, making it difficult to assess 
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the onset of hypogonadism and to determine whether the mutant testis initially had a normal 
number of germ cells.  We conducted histological analysis of the testis during development in 
normal and chagun mutant newborns through adulthood using the Poc1a exon 8 genotyping to 
identify mutants.  Periodic acid-Schiff (PAS) histological staining of testis sections was 
conducted on mice from postnatal day 1 (P1), P7, P14, P21, and 3 months (Figure 3.5).  The 
reduced size of the mutant tubules and reduction in germ cells are both highly progressive, with 
the phenotype manifesting as early as P7 (Figure 3.5).  Near birth (P1), the number of nuclei per 
tubule and the size of the seminiferous tubules of chagun males are indistinguishable from wild 
type, suggesting that germ cell migration to the testis occurred normally.  By P7, the mutant 
tubules appear smaller in diameter.  By P14, the testis is already beginning to exhibit the 
hallmarks of the adult chagun testis phenotype, with obviously smaller tubules, a highly 
vaculolated appearance, and lack of maturing sperm.  The testis of sexually mature 12 wk old 
mice normally contain all stages of sperm development, but the chagun testis has only a single 
layer of cells lining the inner face of the basement membrane, with open spaces spanned by 
Sertoli cell projections giving the tubules the appearance of Sertoli only syndrome due to the 
near absence of germ cells in the tubule (26). 
chagun males have spermatogonial stem cells at P7 and three months of age 
 The progressive loss of germ cells could have many etiologies including depletion of 
spermatogonial stem cells because of a failure in asymmetric cell division, proliferation or cell 
death.  To differentiate between these possibilities, we conducted immunohistochemistry using a 
primary antibody against PLZF (promyelocytic leukemia zinc finger protein), a transcriptional 
regulator of spermatogenic stem cell maintenance and marker for that cell type (27).  At P7 
spermatogenic stem cells begin to express PLZF, and chagun testes have a comparable number  
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Figure 3.5. chagun males exhibit progressive germ cell loss. Panel A. Periodic acid-Schiff 
histological staining of paraffin sections through testes at the ages indicated emphasize the 
progressive nature of the chagun testis phenotype.  Near birth, chagun tubules resemble wild-
type seminiferous tubules, but by sexual maturity, the Poc1acha/cha tubules are practically devoid 
of germ cells. (N=3 animals of each genotype at all timepoints)  Panel B. Leydig cells of chagun 
animals appear normal (N=3 of each genotype at 3 months, L=Leydig cells).  All images 
acquired using a 63X objective lens. 
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of PLZF+ cells to the controls (Figure 3.6).  At 3 months of age, the number of PLZF+ cells per 
tubule is indistinguishable in chagun and control seminiferous tubules, suggesting normal cell 
division and cell death of stem cells.   Increased numbers of pyknotic nuclei suggest increased 
cell death at later stages of germ cell development (26). Experiments are underway to assess cell 
death and proliferation directly using TUNEL staining and EdU incorporation, respectively.  
 
Figure 3.6. chagun testes retain spermatogenic stem cells at sexual maturity.  
Immunohistochemistry was carried out with a primary antibody against PLZF, a marker of 
spermatogenic stem cells, and developed with TSA-FITC Kit from Perkin-Elmer.  Testis sections 
are shown for wild type and chagun mutants at postnatal day 7 and 3 months.  DAPI counterstain 
identifies the nuclei (blue) All images acquired using a 63X objective lens.  (N=3 animals of 
each genotype at both timepoints). 
 
The Sertoli cell contributes to the chagun testis phenotype 
Defects in the germ cells or a class of somatic cells of the testis, the Sertoli cells, can lead 
to testis phenotypes like the one observed in chagun males.  In order to address the function of 
the chagun microenvironment established by the Sertoli cells, we conducted testis stem cell 
transplantation assays (28).  Busulfan is a chemotherapeutic alkylating agent that causes 
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irreparable adenine-guanine crosslinks leading to death of rapidly dividing cells.  Doses of 
busulfan have been determined that will kill spermatogenic stem cells, but preserve the ability of 
the testis to be re-colonized with normal donor spermatogenic cells, although there may be some 
variability in the doses that can be tolerated.    
Rosa-LacZ labeled spermatogenic stem cells from a normal, immuno-compatible donor 
male were transplanted into four chagun recipients and four busulfan treated controls (Jon 
Oatley, Ph.D., Washington State University).  After allowing two months for the donor cells to 
colonize the recipient testes and resume the spermatogenic program, the recipients were assessed 
for X-gal staining to detect engraftment of the Rosa-LacZ labeled donor cells.  In the control 
animals, spermatogenic colonies positive for LacZ expression (dark blue) were observed (Figure 
3.7) (N=4).  No donor-derived colonies were observed in mutant animals (N=4).  These 
preliminary data suggest that the chagun Sertoli cell-generated microenvironment is incapable of 
supporting repopulation by wild-type spermatogenic stem cells. 
Discussion 
 Here we report the discovery of the genetic basis of skeletal dysplasia, growth 
insufficiency, and progressive germ cell loss in chagun mutants.  A LINE-1 retrotransposon-
mediated insertion of a processed transcript into the gene that encodes protein of centriole 1A 
(Poc1a) causes elimination of the C-terminal end of a highly conserved WD-40 domain and 
reduced function. We conclude this based on: 1) identification of an insertion that causes exon-
skipping in Poc1a, 2) co-segregation of this Poc1a mutation with the chagun mutant phenotype, 
3) the lack of mutations in coding regions of any other genes within the chagun critical interval,  
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Figure 3.7 The chagun Sertoli cells fail to support colonization of wild-type spermatogenic 
stem cells.  Whole testis were removed, stained with X-gal, and photographed.  X-gal stained 
spermatogenic colonies (arrows, dark blue color) of labeled wild-type germ cells are present in 
the busulfan-treated control recipient testes (top panel), but no colonies were noted in chagun 
recipient testes (lower panel). 
 
4) expression of Poc1a in the affected tissues, and 5) the report of independent families with 
severe short stature and either a missense or nonsense mutation in POC1A that appear to cause 
partial loss of function.   Taken together, this provides compelling evidence that the insertion in 
Poc1a causes the chagun phenotype.  
 This mutant allele of Poc1a is caused by a LINE-1 mediated insertion of a processed 
transcript from the gene that encodes centromere protein w (Cenpw) into exon 8 of Poc1a.  The 
insertion increases the size of exon 8 by approximately 500 bp.  This is the likely cause of exon 
Wild Type chagun
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skipping, as increasing the size of exons can lead to exon skipping (29).  Transcripts that skip 
exon 8 maintain the open reading frame and are predicted to produce a mutant protein that lacks 
23 amino acids in the WD40 repeat domain in POC1A. There are normal levels of Poc1a 
transcript and protein in mutant tibia, suggesting that the mutant transcript and protein are stable. 
The 23 amino acids missing in the mutant are 71% conserved down to Tetraurelia 
(paramecium), meaning that they are likely critical for the optimal function of Poc1a.  Taken 
together, we conclude that this mutant allele of Poc1a is a hypomorphic or reduced function 
allele, rather than a null allele.   
 Two mutations in POC1A (p.Arg81stop and p.Leu171Pro) were found in consanguineous 
pedigrees with severe short stature (22, 23).   The associated clinical features, including viability 
and the effects on hair, nails and intellectual ability, varied amongst the affected individuals in 
the families.  Sarig, Sprecher and colleagues labeled the syndrome a primordial dwarfism called 
SOFT (short stature, onychodysplasia, facial dysmorphism and hypotrichosis) Syndrome (22), 
although it is not clear that this acronym is appropriate for all patients with POC1A mutations.  
The fertility of the subjects was not discussed, although some were still children.  Alkurava and 
colleagues showed that the patient’s skin-derived fibroblasts exhibit disruptions in mitotic 
spindle orientation and polarity, shortened primary cilia, and a lower frequency of primary cilia 
formation (23).  Golgi trafficking is disrupted in patient fibroblasts with the point mutation 
(p.Leu171Pro) (22), although it is possible that the mutant protein itself is causing Golgi stress.  
This possibility was not explored in these patient fibroblasts.  The basis for the patient's variable 
features is not clear, nor is the mechanism by which POC1A mutations cause growth 
insufficiency.  
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 Cell division in the growth plate is an intriguing process in which chondrocytes rotate and 
move to form the coin-stack structure after polarized cell division in the plane perpendicular to 
the axis of the growth plate (6).  The primary cilium has been implicated in maintaining growth 
plate organization (3).  Conditional loss of intraflagellar transport machinery, which is required 
for the maintenance of the primary cilium, in mouse chondrocytes results in growth insufficiency 
and disorganized growth plates that resemble the Poc1acha/cha growth plate. Deficiencies in 
mitotic spindle orientation and primary cilium formation suggest the mechanism leading to 
growth defects in humans and mice with POC1A mutations.  
We considered the possibility that a defect in the hypothalamus or pituitary could 
contribute to the infertility of Poc1a mutants.  Testosterone levels in Poc1acha/cha animals are 
normal, seminal vesicles appear well developed, and Leydig cells appear normal (26).  This 
suggests that the neuroendocrine portion of the male reproductive axis is working properly, 
implicating defects in germ cells and/or Sertoli cells as the cause of infertility.  There are no data 
that prove that precisely oriented cell division or primary cilia are required for spermatogenesis.  
POC1A regulates centrosome maturation in vitro (30).  If the centrosome fails to mature in 
Poc1acha/cha germ cells, it could lead to spermatogenic arrest and/or a high rate of spermatogenic 
cell death due to faulty cell division.  First, we must complete reciprocal testis transplantation 
assays (28) to determine whether Poc1acha/cha spermatogenic stem cells are capable of 
establishing a spermatogenic program in a wild-type Sertoli cell microenvironment.  If they are 
not capable of colonizing wild-type testes, then further characterization will be necessary, 
including, but not limited to, molecular analysis of centrosome maturation, cell proliferation, and 
cell death in Poc1acha/cha germ cells, both in vivo and in vitro.  These analyses would determine if 
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any or all of these cellular processes are leading to the development of the testis phenotype in 
Poc1acha/cha animals.   
Preliminary results suggest that Poc1acha/cha Sertoli cells are dysfunctional (Figure 3.7).  If 
this is clearly confirmed in additional experiments, the role of Poc1a in Sertoli cells will be 
pursued.  SOX9, an HMG family transcription factor and marker of Sertoli cells, appears to be 
expressed normally in Poc1acha/cha testes, as assessed by immunostaining (data not shown).  
POC1A may regulate the Sertoli cell microtubule network, and/or it may be required for 
formation and function of the Sertoli cell primary cilium.  Sertoli cells are required for the 
formation of a supportive spermatogenic microenviroment.   
Why does the Poc1acha/cha mutation seem to affect only skeletal growth and male fertility?  
Poc1a and the related Poc1b gene are broadly expressed, and, knock-down of both genes by 
siRNA is necessary to cause defects in mitotic spindle orientation in cell lines (HeLa) (30).   The 
overlapping functions of these genes could provide compensation in tissues where both genes are 
expressed.  Further work is necessary to determine whether or not Poc1b is also expressed in 
testis and bone.  Alternatively, the affected tissues may have a requirement for both Poc1a and 
Poc1b.   
The Poc1acha/cha mutant phenotype may stem from a sensitivity of specific cells to 
compromises in mitotic spindle formation.  Human patients with mutations in POC1A exhibit a 
wide range of phenotypes.   Skin, hair, and fingernails can be affected (22).  Some of the patients 
with failure to thrive have difficulty feeding early in life (23).  These features are not seen in 
Poc1acha/cha animals on the FVB/NJ strain.  Any organ system that has high cellular turnover (the 
growth plate, seminiferous epithelium, intestinal epithelium, the skin, hair, and fingernails) could 
be particularly vulnerable to a partial loss of Poc1a function.   
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On the C57BL/6J genetic background, Poc1acha/cha animals are sickly.  In fact, if the 
mutation is backcrossed for six generations onto this genetic background, no mutant animals are 
detected at weaning (data not shown).  It is highly likely that one or more genetic modifiers 
sensitize the C57BL/6J strain to effects of the Poc1a mutation.  For example, strain specific 
allelic variation in genes that encode other components of the cilia and/or centromere could 
enhance or suppress the effects of the Poc1a mutation.  Future work will be centered on 
understanding how the C57BL/6J genetic background contributes to lethality and failure to 
thrive. 
Like the human cases (23), the causative mutation in the Poc1acha/cha mouse likely causes 
a hypomorphic allele of Poc1a that leads to the deletion of 23 amino acids in the translated 
protein.  The loss of these residues could alter the ability of POC1A to localize to the centrosome 
(31).  We show evidence that the protein is expressed in the growth plate of long bones and the 
seminiferous tubules of the testis (Figure 3.3), which are the tissues with the most obvious 
cellular phenotype (Figure 3.4 and 3.5).  More work is necessary to determine the molecular 
bases of the growth defect and male infertility in this mouse model of SOFT Syndrome, but we 
provide much information as to the potential roles that Poc1a plays in vivo.  Additional work 
utilizing the Poc1acha/cha mouse could provide highly valuable information on the molecular 
mechanism behind the many facets of the SOFT Syndome phenotype.  This mouse model also 
highlights male fertility as a potential area of future interest for clinicians examining adult male 
SOFT Syndrome patients.  
The Poc1acha/cha mouse serves as a model of primordial dwarfism.  Many novel genetic 
causes of the various forms of primordial dwarfism have been reported in the recent literature.  
There is also a high likelihood that these disorders, depending on their genetic causes, could be 
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considered skeletal ciliopathies.  SOFT Syndrome and Meier-Gorlin Syndrome are two examples 
of primordial dwarfisms that also lead to defects in the primary cilium (23, 32), but not much is 
known about the molecular mechanism underlying these conditions.  It is for this reason that 
mouse models like the Poc1acha/cha mouse, are an incredibly valuable resource for geneticists. 
Materials and Methods 
Discovery and husbandry of chagun mice.  The chagun phenotype arose spontaneously on the 
DBA/2J strain in Linda Siracusa’s laboratory at the Thomas Jefferson University (Philadelphia, 
Pennsylvania).  The mice were transferred to the University of Michigan (Ann Arbor, Michigan).  
Recently they have been maintained on a hybrid background consisting of C57BL/6J and 
DBA/2J background strains, and also outcrossed to the FVB/NJ strain, and maintained.  
 All mice were housed in a specific pathogen free facility with 12-h light, 12-h dark cycle in 
ventilated cages with unlimited access to tap water and Purina 5020 chow.  All procedures using 
mice were approved by the University of Michigan Committee on Use and Care of Animals 
(UCUCA), and all experiments were conducted in accordance with the principles and procedures 
outlined in the National Institutes of Health Guidelines of the Care and Use of Experimental 
Animals.  
chagun Genotyping Protocol.  Before the mutation was uncovered, primers were used to 
amplify regions around SNPs by conventional PCR methods that differed between the mutant 
(DBA/2J) and the wild-type (FVB/NJ) backgrounds (SNPs: rs30174769, rs29637716) that are 
within the critical interval.  These amplification products were then digested with Bsr1 
endonuclease and run on a 2% agarose/tris-boric acid-EDTA gel to visualize the different bands 
that segregated differentially between the two background strains.  C57BL/6J alleles matched 
that of the wild-type background, FVB/NJ, so if any residual C57BL/6J background remained, 
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we could still determine which mice were heterozygous or homozygous for the mutant (DBA/2J) 
background.  Once the mutation was uncovered, primers designed to detect the presence of the 
insertion from flanking sequence (two potential products; a small wild-type allele, and the larger 
chagun allele with the insertion) were used to distinguish mutants, heterozygous, and wild-type 
animals.  All primers anneal optimally at 60°C.  Primer sequences:   
rs30174769 Fwd: 5’-TGAGCGCCAACACAGTAAAAA-3’  
rs30174769 Rev: 5’-GTGGGAGCAAGAGACAAAGAGAT-3’ 
rs29637716 Fwd: 5’-GCGGGGTGCCTGGGTCTCC-3’ 
rs29637716 Rev: 5’-TCATACAGCACACGCACTTACACA-3’ 
WT and chagun allele Fwd: 5’-TGTCCCACTGCCACTGCCACTCA-3’ 
WT and chagun allele Rev: 5’-GGAAGACTCGCCCCACAGGACTCA-3’ 
Capture of the chagun critical interval.  Targeted enrichment libraries corresponding to the 
chagun critical interval were generated by Daniel Burgess, Ph.D. at Roche/Nimblegen (Madison, 
Wisconsin).  Genomic DNA samples from both a heterozygote (known carrier) and a chagun 
mutant were supplied to generate the libraries, which were indexed separately to allow for 
simultaneous sequencing.  The libraries were sequenced by the University of Michigan DNA 
Sequencing Core led by Robert Lyons, Ph.D. (Department of Biological Chemistry).  
Bioinformatic analyses of the sequence data were performed by James Calvalcoli, Ph.D. 
(Department of Computational Medicine and Bioinformatics, University of Michigan, Ann 
Arbor, Michigan).  The Broad Institute’s Integrative Genomics Viewer was utilized to visualize 
and evaluate the DNA sequence data. 
PCR Amplification of Genomic DNA.  The region around Poc1a exon 8 was amplified by PCR 
of genomic DNA using the following primer sequences:  Forward primer: 5’-
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TGTCCCACTGCCACTGCCACTCA-3’, and Reverse Primer: 5’-
GGAAGACTCGCCCCACAGGACTCA-3’.  Optimal annealing temperature: 60°C.  PCR was 
conducted with the GoTaq DNA Polymerase and buffers provided by the distributor (Promega). 
Extraction of RNA and Generation of cDNA via Reverse Transcription.  Extraction of total 
RNA was completed with the RNAqueous 4-PCR Kit (Ambion) according to the manufacturer’s 
instructions.  The total RNA was utilized to generate cDNA with Oligo dT Primers 
(Invitrogen/Life Technologies) and Superscript II Reverse Transcriptase (Invitrogen/Life 
Technologies) according to the manufacturer’s instructions.  The cDNA was used as a template 
in standard PCR reactions using GoTaq DNA Polymerase (Promega) and the following primers 
to amplify two regions in the Poc1a cDNA:   
Exon 5-10 Forward Primer: 5’-CAAGACCAGCCGGGAATGTATC-3’ 
Exon 5-10 Reverse Primer: CTGGGGCTCGCCTTGAACTGACTC-3’   
Optimal annealing temperature: 60°C.   
Exon 7-8 Forward Primer: 5’- CCATCGGGAAACTACCTCATCAC-3’  
Exon 7-8 Reverse Primer: 5’-AAATACTCCCCCGTTCTTG-3’   
Optimal annealing temperature: 55°C. Sequencing was completed by the University of Michigan 
DNA Sequencing Core. 
Real-Time Quantitative PCR. Real-time quantitative PCR was conducted using cDNA 
generated in the manner stated in the previous Methods section.  TaqMan® Universal PCR 
Master Mix (Applied Biosystems/Life Technologies) was used according to the manufacturer’s 
instructions.  The following TaqMan® probes were included to test expression levels of Poc1a:  
Exon 2-3 Assay ID: Mm01235877_m1.  Exon 10-11 Assay ID: Mm01235875_m1.  Reactions 
	   118	  
were loaded into MicroAmp® Optical 96-well reaction plates (Applied Biosystems/Life 
Technologies) and run using an Applied Biosystems 7500 Real-Time PCR System. 
POC1A Western Blot Analysis.  Isolation of protein from postnatal day 3 tibiae and western 
blot analyses were carried out as previously described (33).  The blot was incubated with a 1:500 
dilution of a mouse anti-human POC1A primary antibody (Abcam, ab67698) overnight at 4°C.  
The blot was incubated with a 1:5000 dilution of a goat anti-mouse IgG secondary antibody 
(Jackson ImmunoResearch Laboratories, Inc. #115-035-003) for one hour at room temperature.   
The blot was stripped and incubated with a 1:5000 dilution of a rat anti-yeast tubulin antibody 
(Abcam, ab6160) overnight at 4°C.  The blot was incubated with a 1:10,000 dilution of a goat 
anti-Rat IgG secondary antibody (Jackson ImmunoResearch Laboratories, # 112-035-102) for 
one hour at room temperature.  All antibodies were diluted in a blocking solution made up of 1% 
weight:volume Bovine Serum Albumin;Tris-buffered saline with Tween-20. 
Bone and Testis Histology. Tibiae were dissected from two and three-week old male animals, 
fixed overnight in 4% PFA, rinsed in PBS, and decalcified in 14% EDTA solution 
(weight:volume) for approximately 30 days.  Testes were removed from mice of the listed ages, 
fixed overnight in Bouin’s Fixative Solution (Sigma).  Both the testes and tibiae were then 
dehydrated through an ethanol series and embedded in paraffin.  Sections were stained with 
hematoxylin and eosin (tibiae) or periodic acid-Schiff’s reagent (testes) according to standard 
protocols.   
POC1A Immunohistochemistry.  Immunohistochemistry was conducted by deparaffinization 
of the slides in xylenes and rehydration in an ethanol series to 1X PBS.  Afterward, the testis 
sections were boiled in a 100 mM solution of citric acid (pH 6.0) for 10 minutes to expose 
epitopes, and cooled.  Tibia sections were fixed for 7 minutes in 4% PFA, washed in PBS, and 
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were not subjected to heat-induced epitope unmasking in citric acid.  Both testis and tibia 
sections were incubated for 20 minutes in solution of 3% hydrogen peroxide diluted in methanol 
to quench endogenous peroxidase activity.  The slides were blocked in a solution included in the 
Tyramide Signal Amplification (TSA) Kit  (Perkin-Elmer) for one hour at room temperature.  
This was followed by an overnight incubation with a rabbit anti-rat POC1A primary antibody 
(Abcam, ab135361) diluted 1:100 in TSA Block solution at 4°C.  Sections were washed in PBS, 
and incubated with a goat anti-rabbit biotin-conjugated secondary antibody (Jackson 
ImmunoResearch Laboratories Inc., #111-067-003) for 1 hour at room temperature.  The 
subsequent steps were carried out according to the instructions provided in the TSA Fluorescein 
Tyramide Kit (TSA-FITC Kit) by Perkin-Elmer.  Sections were counterstained with DAPI to 
reveal nuclei, cover slipped and photographed with a Leica Leitz DMRB/E compound 
microscope. 
PLZF Immunohistochemistry.  The POC1A primary antibody was used in 
immunohistochemical analysis of testis sections from the ages listed.  The rabbit anti-human 
PLZF primary antibody (Santa Cruz Biotechnology Inc., sc-22839) was incubated at a 1:50 
dilution in the TSA Block Solution overnight at 4°C, and treated in the same manner as the 
sections incubated with the POC1A primary antibody (TSA-FITC Kit, Perkin-Elmer). 
Testis Cell Transplantation Assays.  Assays were performed at Washington State University 
(Pullman, Washington) in the laboratory of Jon Oatley, Ph.D. as previously described (34). 
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APPENDIX 3.1 
Appendix 3.1. Variants Unique to chagun Uncovered Via Whole Exome Sequencing 
Gene Name Gene Name and 
Function 






Ephb1 Eph receptor B1 
Ephrin signaling 




Cpne4 Copine IV 6X Insertion (+TT) 104588727 In Poly-T Tract 
57X 
 
SNP (AàG) 105337374 
 
Not in splice 
site or branch 
point 
Atp2c1 ATPase, Ca+2 
sequestering 
Secretory pathway 
59X Deletion (-1) 105337375 Not in splice 














In a CA-repeat 
 
Col6a6 Collagen, type VI, 
alpha 6 
 8X Insertion (+G) 105641565 Not in a splice 
site or branch 
point 
9X Deletion (-G) 105969540 In Poly-G Tract Col6a4 Collagen, type VI, 
alpha 4 
 
8X SNP (CàT) 105969546 In Poly-G Tract 
Alas1 Aminolevulinic acid 
synthase 1 
Embryonic lethality 
48X SNP (TàG) 106136553 In Poly-T Tract 
Acy1 Aminoacylase 1 
Catalyzes N-acetyl 
amino acids to 
amino acid and 
acetic acid 
170X SNP (AàG) 106337184 Not in splice 




2X SNP (AàG) 106377303 Not conserved, 
in poly-G tract 




2X SNP (AàG) 106377304 Not Conserved, 
in poly-G tract 
Note: All variants listed above occur in introns. 
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APPENDIX 3.2 
Appendix 3.2. Novel Insertions Uncovered By Targeted Enrichment of the chagun Critical Interval 







Number of Reads Description 
103901307 103901445 IAPLTR1a_I_MM 4 Overlaps a known 
RSINE element 
105278767 105278878 RLTR25_MM 6 Located in the 
middle of intron 1 
of Nek11 
105462434 105463009 L10 17 Located between 
two MTA repeats 
105538508 105538828 B2_Mm1a 6 Intergenic 
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CHAPTER 4 
Future Directions in Skeletal Dysplasia and Infertility Genetic Research 
Introduction 
In this dissertation I present the identification of the genetic basis of two skeletal 
dysplasia and infertility syndromes.  These studies reveal the pathophysiology of disease, and set 
the stage for the development of therapeutic interventions.  These two examples typify two 
current prominent themes in skeletal dysplasia research.  First: novel genetic causes of disease 
are being discovered at a phenomenal rate, largely due to high-throughput mapping and 
sequencing technologies.  Second: mouse models are invaluable for understanding the molecular 
etiologies behind skeletal dysplasia phenotypes.  Chapter 1, which focuses mainly on the first 
theme, clearly demonstrates the shift in strategy toward utilizing next-generation technologies, 
and how these technologies have been used in the last two years to the investigator’s advantage 
(Table 1.2).  They will also likely be used in future work to address the remaining forms of 
skeletal disorders that currently have no known genetic cause, as well as many novel skeletal 
disorders that are only now being recognized (Table 1.4).   
Chapters 2 and 3, on the other hand, focus on the second theme.  While both mouse 
models presented in this dissertation harbor mutations in genes previously shown to cause human 
skeletal disorders, both models are highly valuable in that they allow us to pursue a deeper 
characterization of the phenotype, which will ultimately add to our basic understanding of
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skeletal growth and development, and could lead to potential therapies for skeletal dysplasia 
patients (Chapter 2). 
There is still much to be done with regard to future exploration concerning both of these 
themes.  There are multiple additional experiments that could be conducted with regard to 
understanding the mechanisms behind both the Npr2pwe/pwe and the Poc1acha/cha mutant 
phenotypes.  There is also the potential of developing therapies (Poc1acha/cha) or refining 
therapeutic intervention (Npr2pwe/pwe) in both of these mouse models.  While there are still 
unanswered genetic questions regarding the causes of many skeletal disorders, there are even 
more questions regarding potential modifying loci that contribute to the phenotypic variability 
reported in some forms of skeletal dysplasia.  There are a number of approaches one could take 
to address these questions, including sensitized mutagenesis screens in mouse or zebrafish.  All 
of these future directions will be discussed in the sections that follow. 
Npr2pwe/pwe: Molecular Outputs of CNP/NPR2 Signaling 
 Much that has been gained from the understanding of C-type Natriuretic Peptide 
(CNP)/Natriuretic Peptide Receptor 2 (NPR2) signaling has come from work conducted in cell 
lines (1) or on whole fetal tibiae treated with CNP and pharmacological inhibitors in culture (2).  
These studies have shown that two of the main signaling cascades regulated by CNP are the 
MEK/ERK (1) and p38 Mitogen-Activated Protein Kinase (2) (MAPK) pathways.  Of course, 
with the development of many mutant alleles in these pathways, there exists the potential to cross 
these lines to determine the relative contributions of these pathways to bone growth.  For 
example, gene expression profiling on animals with gain or loss of function of these genes in 
combination (Npr2pwe/pwe, Mkk3-/- or Mkk6-/- double mutant animals, which would be unable to 
activate p38 MAPK components) could define the gene expression profile regulated by p38 
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MAPK in comparison to control animals.  The same could be done utilizing gain and loss of 
function of Fgfr3, or loss of function of Mkk1 in tandem with loss-of-function in Npr2 to 
uncover the genes regulated by these signaling pathways.  Taking a genetic approach and 
analyzing fetal tibiae immediately as opposed to after 6-8 days of culture (2) could reduce 
potential artifacts generated as a result of the in vitro environment.  Additionally, the genes 
regulated by these various pathways could provide clues of further cross-talk between these 
pathways and other signaling pathways.  This could provide information on additional 
therapeutic avenues for AMDM, similar to the way CNP became a major therapeutic candidate 
for achondroplasia (3).  Obviously, models for AMDM, such as the Npr2pwe/pwe mouse, will be 
valuable assets for the testing of these potential therapies. 
Npr2pwe/pwe: Improving the Therapy For the Growth Defect 
 It is difficult to deliver therapy directly to the growth plate through the circulation 
because the growth plate is an avascular tissue (4).  Systemic delivery of drugs to treat mouse 
models of skeletal dysplasia has had mixed success (5-10).  The most successful strategy was 
continuous supplementation with CNP in mice (6), or genetic manipulation to overexpress CNP 
in models of achondroplasia (11, 12).  In terms of developing an easily administered therapy for 
human patients, which would most likely be children at the time of therapeutic intervention, 
neither of the more successful methods is a feasible or desirable mode of therapy.  This is due to 
the fact that continuous supplementation intravenously during one’s childhood could affect one’s 
quality of life, and we are unable at this time to provide gene therapy.  If, however, targeting to 
the growth plate could somehow be improved, this would undoubtedly increase the success rate 
of these pharmacological therapies, and minimize off-target effects on other tissues.   
	   128	  
In order for a treatment to be deemed successful, it should not only increase growth 
velocity and allow the individual to reach their target height in a proportional manner, it should 
also cause minimal effects on the integrity of the skeletal elements themselves.  In the case of 
continuous supplementation of CNP or a drug, it is possible that the increase in the growth rate 
could come at the expense of healthy long bones.  In the case of MEK1/2 inhibition (5, 13), 
continuous supplementation could potentially accelerate the rate of long bone growth, but also 
cause a failure in osteoblast differentiation, a process that requires activation of ERK1/2 (14).  
Further, acceleration of growth plate chondocyte proliferation or hypertrophic differentiation 
could lead to a scenario wherein the osteoblasts cannot meet the demand for the addition of bone 
matrix.  Likewise, the cells of the growth plate may be depleted more quickly than they should 
due to increased proliferation and/or differentiation.  Both of these outcomes could impair the 
patient’s ability to reach their target height, and/or affect the quality of mineralized tissue that 
forms.  Dosage, administration method, duration of treatment, and improved targeting to the 
growth plate are imperative areas of future work to consider as we move forward toward 
developing therapies for skeletal dysplasia patients. 
Npr2pwe/pwe: CNP/NPR2 Function in the Ovarian Follicle in Mouse and Human 
 Recent work on CNP and NPR2 in the regulation of meiotic arrest have shown that Npr2 
mRNA expression in isolated cumulus cells is increased by estradiol treatment in vitro (15).  
Estradiol also increased cGMP levels in cumulus cells and oocytes, presumably by increasing the 
expression of NPR2 (15).  Hseuh and colleagues showed that treatment with hCG (LH analog) 
leads to a decrease in Nppc (CNP) mRNA expression in granulosa cells of ovarian follicles (16), 
while Jaffe's group showed that LH reduces NPR2 activity, as evidenced by a reduction in cGMP 
levels in ovarian follicles (17).  All of these data support a clear role of endocrine regulation of 
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the CNP/NPR2 signaling pathway to maintain meiotic arrest.  Additional data generated after an 
ovulatory dose of hCG in human patients demonstrated a decrease in CNP level in human 
follicular fluid (16).  These data are the first to provide support that this pathway could be 
mediating oocyte meiotic arrest in human. 
 The data generated provide strong evidence implicating CNP/NPR2 in maintaining 
meiotic arrest in human oocytes.  This raises an obvious question: are female AMDM patients 
fertile?  First, the rarity of AMDM (18) makes it difficult to obtain information about fertility.  I 
predict that women with this disorder would be infertile due to failed meiotic arrest, but they 
may be able to carry pregnancies with donor eggs.  The study of female AMDM patients over 
time could be conducted to determine if in fact these patients are infertile.  Of course, this would 
also provide support that the CNP/NPR2 signaling pathway is likely regulating oocyte meiotic 
arrest in human.   
Poc1acha/cha: Proof that the correct gene has been identified. 
 In Chapter 3, many lines of evidence are presented that support the hypothesis that the 
chagun mutant phenotype is caused by a hypomorphic allele of Poc1a (Figure 3.1, Figure 3.2).  
We are confident that this is the causative mutation.  No other obviously deleterious variants 
were uncovered through whole exome sequencing (Appendix 3.1). We also discovered five 
novel insertions in the critical interval that are not present in 16 reference strain genomes 
(Appendix 3.2).  We will use a combination of bioinformatic analysis and PCR amplification to 
determine that these are true insertions, and confirm the presence or absence of these elements in 
the parental strains (FVB/NJ, DBA/2J, C57BL/6J).  If any are found to be unique to the chagun 
strain, we will determine whether or not the insertion alters gene splicing (intragenic insertions) 
or gene expression (intergenic insertions).  Importantly, the insertion of the processed 
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pseudogene (Cenpw) into exon 8 of Poc1a is the only variant we have found that will likely 
disrupt the function of an encoded protein.   
There are two experiments that could provide additional genetic evidence that Poc1a is 
the gene causing the chagun mutant phenotype.  First, we are conducting a Bacterial Artificial 
Chromosome (BAC) transgenic rescue experiment using a BAC (RP24-384G5, 196,267 bp) that 
contains Poc1a and approximately 75 kb and 50 Kb of flanking sequencing on the on the 
proximal and distal ends of Poc1a, respectively.  The BAC is likely to contain all of the elements 
required for Poc1a expression.  Crossing the transgenic mice harboring the BAC to our chagun 
strain will allow us to determine whether providing mutants with one functional copy of Poc1a 
corrects the phenotype.  The BAC contains 3 additional genes: Twf2, Alas1, and Dusp7.  All 
three of these genes are not likely to be causing the mutant phenotype.  The knock-out allele of 
Twf2, which encodes twinfilin, actin binding protein, homolog 2, does not exhibit a phenotype 
(19).  Alas1 (aminolevulinic acid synthase 1) knock-out animals die early in embryonic 
development (20), and only minor variants were uncovered by whole exome sequencing 
(Appendix 3.1).  Furthermore, no insertions were uncovered in this gene through targeted 
enrichment and sequencing of the entire critical interval.  Dual specificity phophatase 7 (Dusp7) 
does not have a knock out allele as of yet, but no variants were uncovered through either of the 
two methods we employed.  Thus, our choice of BAC appears to confer all the proper 
information to allow for Poc1a expression, while limiting the number of additional genes, all 
three of which are unlikely to cause an issue or be causing the mutant phenotype.   
An alternative approach is to conduct an allelism test.  This would involve crossing our 
Poc1acha/cha strain with a Poc1a-/- strain to determine whether compound heterozygotes exhibit 
the homozygous Poc1acha/cha phenotype.  However, given that the Poc1acha/cha allele is 
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hypomorphic, and the mutations in human patients are also thought to be hypomorphic alleles, it 
is likely that a true knock-out allele of Poc1a will be lethal.  Therefore, it may be impossible to 
generate mice from the Poc1a knock-out ES cell clones we are in the process of obtaining 
(Knock-Out Mouse Project, KOMP).   If so, it would be helpful to determine the embryonic 
stage in which the animals die, as we could utilize yet another alternative approach—an 
inducible cre recombinase to bypass the global knock-out’s potential early embryonic lethality.  
Conversely, if mice are born, we will have to rigorously compare the Poc1a knock-out 
phenotype to the Poc1acha/cha phenotype to see what differences exist.  Crossing the knock-out 
allele onto the Poc1acha/cha background would generate compound heterozygotes which could 
exhibit an intermediate phenotype: worse than the Poc1acha/cha homozygous phenotype, but less 
severe than the knock-out phenotype. Both the BAC transgenic rescue and the allelism test will 
provide us with additional supporting evidence that the hypomorphic allele of Poc1a in chagun 
animals is indeed responsible for the mutant phenotype. 
Poc1acha/cha: Molecular characterization of the hypomorphic mutation 
 Poc1a is expressed in many tissues, based on cDNA Source Data (Mouse Genome 
Informatics), although no systematic assessment of gene expression has been done.  Given the 
broad expression of Poc1a it is intriguing that hypomorphic mutations in POC1A cause skeletal 
dysplasia and male infertility, but leave other tissues intact.   POC1A, and its close relative, 
POC1B, have both been shown in human cell lines to be required for proper mitotic spindle 
orientation and polarity (21).  These experiments were conducted using siRNA to knock-down 
expression of both POC1A and POC1B, but did not lead to complete depletion of both proteins.  
The defects in the mitotic spindle observed in the knock-down experiment were the same defects 
present in human patient skin fibroblasts.  Therefore, while the data from the knock-down 
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experiment suggest functional redundancy between these related genes, the data from human 
patient cells indicate that even a partial loss-of-function in one gene can affect proper mitotic 
spindle orientation and polarity.   
This begs the question of whether or not there are tissues, such as the bone and testis, that 
are particularly vulnerable to Poc1a partial loss-of-function.  One way to address this question is 
to conduct RT-PCR on an array of tissues to determine where each of them is expressed and 
assess the relative abundance.  With respect to Poc1acha/cha animals, both members may be 
expressed in bone and testis, but the mutation leads to the loss of a critical function conferred by 
the deleted 23 amino acids in Poc1a in both of these tissues.  This could include the loss of a 
binding site of a critical cofactor, leading to its failed recruitment to the centrosome.  It is also 
possible that Poc1a, but not Poc1b, is expressed in these tissues.  Both outcomes could explain 
the tissue specificity of the Poc1acha/cha phenotype encompassing bone and testis.  As discussed in 
Chapter 3, however, there may be subtle defects in tissues with a high demand for cellular 
turnover (skin, hair, fingernails, intestinal epithelium, etc.) due to the predicted functions of both 
of these genes.  Therefore, depending on the outcome of the RT-PCR survey, there may be 
additional aspects of the Poc1acha/cha phenotype that have been overlooked, and could reveal 
more similarities between this mouse model and human patients (22, 23). 
The amino acids deleted in POC1A in Poc1acha/cha animals are located at the C-terminal 
end of the WD40 repeat domain (Figure 3.1D).  While this mutation does not disrupt the open 
reading frame, it is possible that the folding of POC1A is disrupted C-terminal to the loss of exon 
8.  This could lead to suboptimal targeting of POC1A to the centrosome (24).  If, however, 
POC1A does localize to the centrosome, the mutation could lead to the impaired recruitment of 
cofactors to the centrosome.  Based on the phenotypes of human patients’ skin fibroblasts (23), 
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and knock-down experiments in HeLa cells (21), the mutation could be affecting recruitment of 
factors required for proper centrosome maturation, mitotic spindle orientation and polarity, 
primary cilium formation and maintenance, as well as asymmetric cell division.   
To determine if the mutant form of POC1A localizes to the centrosome, one approach 
would be to conduct immunohistochemistry on POC1A and γ-tubulin (centrosome marker) in 
mutant and wild-type mouse embryonic fibroblasts (MEFs).  If mutant POC1A is found to 
localize to the centrosome, then the same primary antibody could then be used for 
coimmunoprecipitation experiments, followed by mass spectrometry, to determine what factors 
associate with wild-type POC1A, and those which fail to associate with mutant POC1A.  Of 
course, these techniques are dependent on the availability of primary antibodies capable of 
recognizing the mutant protein.   
If this proves challenging, an alternative way to test both localization to the centrosome 
and recruitment of appropriate cofactors is to use the biotin-tagging system (25).  This would 
involve generating a construct with a biotin-acceptor tag sequence at the C-terminus of the 
mutant form of POC1A, and co-transfecting this construct into cells with a vector expressing 
BirA, the enzyme that catalyzes the addition of biotin to the biotin-tag sequence.  Cells would 
then express biotin-tagged POC1A, which could be incubated with a streptavidin or avidin-
conjugated fluorophore to visualize POC1A in the transfected cells.  This technique in 
combination with immunohistochemistry for γ-tubulin will allow us to ascertain whether or not 
the mutant form of POC1A associates with the centrosome.   
If necessary, the biotin-tagged POC1A could then also be used in coimmunoprecipitation 
experiments followed by mass spectrometry, to uncover the proteins that typically associate with 
POC1A, and those that are missing from this complex in the mutant.  This approach has the 
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added advantage that biotinylation can also be done in vivo (26), by crossing mice expressing a 
biotin-tag with BirA expressing mice.  Two lines of transgenic mice would be made, one with 
mutant POC1A with a biotin-tag, and one with wild-type POC1A with a biotin tag, both of 
which would be mated to BirA expressing mice (26), to allow for biotin labeling in vivo.  As 
there may be tissue-dependent cofactors associating with POC1A, this approach may provide 
more detailed information regarding the molecular defects in the seminiferous tubules and 
growth plate of Poc1acha/cha animals, and add to our basic understanding of POC1A function in 
both of these tissues. 
Another crucial question to answer regarding the mutant form of POC1A is whether or 
not a critical point in the cell cycle is affected by the mutation.  The potential exists that partial 
loss-of-function of POC1A leads to perturbations in all areas of the cell cycle (Figure 1.3).  
Studies utilizing skin fibroblasts from Meier-Gorlin Syndrome patients indicate that these cells 
do progress through the cell cycle (27, 28), but the gene involved can affect the rate of 
progression through the various phases.  This means that multiple genes implicated in the 
development of a different form of primordial dwarfism can affect the rate of progression 
through the cell cycle, without causing the cells to stop cycling.  Flow cytometry of Poc1acha/cha 
MEFs could clarify if there is a deficiency or augmentation in one or more phases of the cell 
cycle.  This could add much to our understanding of the phenotypes present in both the testis and 
the long bones.  For example, if many cells remain in G2 phase, then it is possible that 
centrosome duplication and/or maturation is one of the primary issues in Poc1acha/cha cells, which 
could affect progression to M phase, and lead to defects in mitotic spindle orientation and 
polarity (21).  This could certainly explain the disorganization of the Poc1acha/cha growth plate, as 
cell polarity and oriented cell division are critical to maintain growth plate architecture (29). 
	   135	  
Along the same lines, it will be important to address the possible dysfunction of the 
mitotic spindle and the primary cilium.  MEFs are an ideal choice for conducting these types of 
experiments.  Inducing the formation of the primary cilium via serum-starvation followed by 
immunohistochemistry for acetylated tubulin (primary cilium marker), will allow us to quantify 
the frequency of cilia formation, as well as measure the lengths of the cilia that form.  
Conversely, culturing MEFs in the presence of serum would stimulate cell division, meaning we 
could capture some of the cells as they are dividing.  Immunohistochemistry for tubulin and γ-
tubulin would allow us to visualize the mitotic spindle and spindle poles, respectively.  This 
experiment would provide us with a means with which to evaluate the mitotic spindle, and 
quantify of the number of centrosomes per cell.  The state of having more than one centrosome 
per cell is known as centrosome amplification.  This phenomenon has been reported in the 
human patient fibroblasts (23) and cells in which POC1A and POC1B were knocked-down by 
siRNA (21).  It is critical to determine if the Poc1acha/cha fibroblasts exhibit these same cellular 
phenotypes.  If so, it would certainly add support to our conclusion that the Poc1acha/cha mouse is 
a model of a novel form of primordial dwarfism in humans, and could provide more clues as to 
the nature of the cellular defects present in the growth plates and seminiferous tubules. 
Primordial dwarfisms are hypothesized to be caused by a state of hypocellularity (30).  
This state is thought to occur by cell cycle arrest or slower progression through the cell cycle, 
leading to a sluggish rate of cellular proliferation, or an increased rate of cell death.  In the 
Poc1acha/cha animal, understanding this balance between cell proliferation and cell death during 
development and in the affected tissues is of high priority.  The use of EdU (5-ethynyl-
2’deoxyuridine), an analog of BrdU (5-bromo-2’-deoxyuridine), to assess proliferation is an easy 
and more sensitive method of detection than BrdU incorporation, which requires the use of a 
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primary antibody.  Injecting the whole animal with EdU will provide a clear view of how the 
mutation is impacting the number of proliferating cells in the affected tissues.  Likewise, 
injecting timed pregnant mothers with EdU will allow us to assess proliferation in whole 
embryos throughout development.  We will also ascertain the level of cell death present in 
affected tissues and throughout embryonic development.  TUNEL (terminal deoxynucleotidyl 
transferase dUTP nick end labeling) staining marks cells undergoing a state of DNA 
fragmentation that occurs as result of committing to apoptosis.  The use of this technique on 
sections through the long bones, testis, and whole embryos will allow us to determine the overall 
effect of the mutation on the rate of cell death.  
Both of these experimental approaches must be conducted at the proper time to allow us 
to see the onset of the cellular phenotype.  In the testis, this may be at birth, which is the state 
where the seminiferous tubules more closely resemble controls (Figure 3.5).  This may also be 
the best time to assess both cellular proliferation and apoptosis in the growth plate, but first we 
must determine the time when the growth plate of Poc1acha/cha animals resembles that of the 
control.  Finally, in the whole embryo, it will be important to try to determine rates of 
proliferation and cell death at a variety of embryonic stages.  A likely starting point would be 
E9.5 (embryonic day 9.5), and every other day thereafter.  This could also provide us with earlier 
time points for proliferation and apoptosis in the two tissues of interest. 
Poc1acha/cha: Understanding the molecular etiology of the growth defect 
 The previous section on understanding how the Poc1acha/cha allele causes its cellular 
phenotypes could provide much guidance in the next steps we take regarding the growth defect.  
First, we must determine the onset of the growth defect in these animals and address the question 
of whether or not the cells are proliferating more slowly or are undergoing more frequent cell 
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death.  Both of these outcomes could be affected by defects in processes mediated by the 
centrosome.  If mitotic spindle orientation and polarity are disrupted, it will be imperative to 
determine if the same is true in the proliferative zone.  Immunohistochemistry for tubulin and γ-
tubulin on many sections through Poc1acha/cha growth plates could provide us the ability to 
visualize the mitotic spindle and spindle poles in the growth plate.  It is likely that the process of 
oriented cell division is disrupted, which is contributing to the disorganization in this tissue.   
Also likely is the reduction in frequency, length, and polarity of the primary cilium in the 
growth plate, an organelle known to be required for proper growth plate organization (31).  WNT 
and Indian hedgehog (IHH) signaling components are known to localize to the primary cilium 
(32).  Defective signaling through both of these pathways could lead to perturbations in 
chondrocyte rotation (WNT) (29), and proliferation and differentiation (IHH) (33).  If the cilium 
is disrupted, Real-Time quantitative PCR on WNT and IHH target genes could provide support 
that these pathways are not functioning properly in the Poc1acha/cha growth plate. 
Poc1acha/cha: What is the cause of male infertility? 
 The first question that needs to be considered with respect to male infertility in 
Poc1acha/cha mice is: what cell type(s) express Poc1a in the testis?  Immunohistochemistry on 
wild-type seminiferous tubules revealed that POC1A is mainly expressed in cells near the lumen 
of the tubule (Figure 3.3).  POC1A expression is detected sporadically in cells near the basement 
membrane of the tubule (data not shown).  This is the location of the lesser-differentiated cells 
(spermatogonia, etc.).  It is not clear at this point whether POC1A is expressed in the somatic 
and/or germ cell compartments.  One way to address this issue is to test for colocalization using 
primary antibodies against various cell populations in the testis.  This will help delineate if 
POC1A is expressed in spermatogenic stem cells, spermatogonia, meiotic germ cells, 
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spermatozoa, and Sertoli cells.  Given that the Poc1acha/cha Sertoli cells are incapable of 
supporting the resumption of the spermatogenic program with wild-type donor germ cells 
(Figure 3.7), it is likely that POC1A is expressed in this cell type.  What it is doing in the Sertoli 
cells, however, remains to be clarified.  
 The next logical question that needs to be answered is how partial loss-of-function of 
Poc1a causes the loss of germ cells in the testis.  It is highly likely that Poc1a is expressed in 
both cell populations.  Therefore, the reciprocal testis cell transplantation assay using Poc1acha/cha 
Rosa-LacZ labeled spermatogenic stem cells will likely show that this cell population is also 
defective at establishing labeled spermatogenic colonies in wild-type testes.  This experiment 
must be conducted to rule out a defect in Poc1acha/cha spermatogenic stem cells.  The possibility 
also exists of culturing spermatogenic stem cells from wild-type animals and knocking down 
Poc1a expression in an attempt to understand the cellular and molecular details of Poc1a 
function in this cell type.   
If both cell populations are defective, this could complicate the analysis of the testis.  
This may require the use of conditional alleles of Poc1a in both cell populations to remove 
Poc1a function in Sertoli cells and various populations of germ cells specifically.  A floxed allele 
of Poc1a would have to be generated for these experiments to be conducted.  Crossing this 
animal to a cell-type specific Cre Recombinase allele would remove Poc1a function in that cell 
type, causing a conditional loss-of-function allele.  To really recapitulate the phenotype, we may 
want to consider floxing exon 8 of Poc1a, as recombination would lead to the loss of this exon in 
the mRNA transcript, and loss of 23 amino acids in the translated protein. 
Diffuse POC1A expression via immunohistochemistry has been noted in some 
seminiferous tubules from wild-type animals, around the areas of the tubule where Sertoli cells 
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surround the germ cells.  This pattern of expression could indicate that POC1A is involved in 
regulating Sertoli cell cytoskeletal dynamics, which is required for the Sertoli cell to optimally 
maintain its connections to the germ cells and promote their progression through the phases of 
spermatogenesis (34).  Currently, there is no known role for the primary cilium in the mouse or 
human testis, but it is possible that the Sertoli cell primary cilium is required for optimal 
signaling events that regulate spermatogenesis.  It is also likely that the Poc1acha/cha Sertoli cells 
generate a supportive niche for spermatogenic stem cells, but that the niche fails in supporting 
the spermatogenic stem cell’s progression to later stages of differentiation.  Rates of 
proliferation, apoptosis, and quantification of the various cell types in Poc1acha/cha animals at the 
proper timepoints will help to answer some of these remaining questions.  Visualization of the 
primary cilium and the Sertoli cell cytoskeleton in Poc1acha/cha animals will provide molecular 
details that could rule out the dysfunction of either the cytoskeleton or the primary cilium in the 
development of the Poc1acha/cha male infertility phenotype. 
As stated previously, patients with mutations in POC1A have either not been extensively 
evaluated for male fertility, or no phenotype was reported at the time of examination (22, 23).  
Clearly, in the area of the growth defect, the Poc1acha/cha mouse serves as a model for this form of 
primordial dwarfism.  Interestingly, it may have also provided clues as to an additional aspect of 
the human phenotype (male infertility) that should be evaluated in future male patients with 
mutations in POC1A. 
Modifying Loci: The New Frontiers in Skeletal Dysplasia Genetics  
 Both mouse models of skeletal dysplasia presented in this dissertation illustrate the 
probable contribution of modifying loci in the development of the mutant phenotype.  The 
Npr2pwe/pwe mouse exhibits a worsening of the phenotype on the C57BL/6J genetic background, 
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and the lower level of lethality on the mixed background differs from what other groups have 
reported in their characterization of other Npr2 loss-of-function alleles on different genetic 
backgrounds (35-37).  The Poc1acha/cha allele is compatible with life on the FVB/NJ, CAST/EiJ, 
and DBA/2J genetic backgrounds.  On DBA/2J, Poc1acha/cha mice exhibit a fully penetrant 
neurologic phenotype, hind leg clasping, but this feature is completely lacking on other 
backgrounds.  Introduction of the C57BL/6J genetic background increases the severity of the 
growth phenotype, and the animals look sickly.  Backcrossing the Poc1acha/cha allele onto the 
C57BL/6J background for six generations results in early embryonic lethality.  These scenarios 
in mice are not unlike the scenarios that arise in human patients—frequently patients with the 
same mutation can have vastly different outcomes, which is likely due to effects of additional 
variants elsewhere in the genome. 
 Hypomorphic alleles like the Poc1acha/cha allele are ideal choices for conducting what are 
known as sensitized mutant screens.  In these cases, there is already a mutant phenotype or 
susceptibility to a mutant phenotype present on the strain to be mutagenized, and the goal is to 
introduce mutations that change the phenotype in some way.  Perhaps the phenotype improves, 
perhaps its severity increases, or, in the case of the Poc1acha/cha allele, leads to a complete loss of 
mutant animals being born.  There are a number of forms of skeletal dysplasia that can cause 
early lethality (38), and their ability to do so can be variable.  The novel form of primordial 
dwarfism caused by mutations in POC1A is an excellent example of this phenomenon.  Many of 
the patients evaluated with the premature termination codon died early in life or lived with some 
major complications (23), while those with the point mutation seemed to fare better (22).  This 
could be due to the differences in the mutations themselves, or a variable incidence of 
translational read-through in some patients with the premature termination codon (23).  It is also 
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possible that there are modifying loci in humans that exacerbate the phenotype, and a mouse 
model such as the Poc1acha/cha animal is an invaluable tool to use to delve into the connections 
between Poc1a and other genomic loci that can potentially influence the mutant phenotype. 
 Modifiers of mutant phenotypes obviously reflect the situation often presented in human 
patients, and for that reason, they are an active area of genetic inquiry.  As the genetic causes of 
skeletal disorders continue to increase in number, it is likely that some of these interactions will 
be addressed and their molecular underpinnings discovered through screens in mouse and 
zebrafish.  Pairing future work on modifiers with the development of therapies that exhibit 
improved targeting to the growth plate, could truly open the field to a new era of personalized 
medicine for patients with skeletal disorders and genetic modifying loci. 
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